<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Korean Neurosurg Soc</journal-id>
<journal-id journal-id-type="iso-abbrev">J Korean Neurosurg Soc</journal-id>
<journal-id journal-id-type="publisher-id">JKNS</journal-id>
<journal-title-group>
<journal-title>Journal of Korean Neurosurgical Society</journal-title>
</journal-title-group>
<issn pub-type="ppub">2005-3711</issn>
<issn pub-type="epub">1598-7876</issn>
<publisher>
<publisher-name>Korean Neurosurgical Society</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31085953</article-id>
<article-id pub-id-type="pmc">6514310</article-id>
<article-id pub-id-type="doi">10.3340/jkns.2019.0027</article-id>
<article-id pub-id-type="publisher-id">jkns-2019-0027</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Mechanistic Target of Rapamycin Pathway in Epileptic Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Jang Keun</given-names>
</name>
<degrees>B.S.</degrees>
<xref ref-type="aff" rid="af1-jkns-2019-0027">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Jeong Ho</given-names>
</name>
<degrees>M.D.</degrees>
<degrees>Ph.D.</degrees>
<xref ref-type="corresp" rid="c1-jkns-2019-0027"></xref>
<xref ref-type="aff" rid="af1-jkns-2019-0027">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="af2-jkns-2019-0027">
<sup>2</sup>
</xref>
</contrib>
<aff id="af1-jkns-2019-0027">
<label>1</label>Biomedical Science and Engineering Interdisciplinary Program, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, <country>Korea</country></aff>
<aff id="af2-jkns-2019-0027">
<label>2</label>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, <country>Korea</country></aff>
</contrib-group>
<author-notes>
<corresp id="c1-jkns-2019-0027">Address for reprints : Jeong Ho Lee, M.D., Ph.D. Biomedical Science and Engineering Interdisciplinary Program, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Korea Tel : +82-42-350-4246, Fax : +82-42-350-4240, E-mail : <email>jhlee4246@kaist.ac.kr</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>1</day>
<month>5</month>
<year>2019</year>
</pub-date>
<volume>62</volume>
<issue>3</issue>
<fpage>272</fpage>
<lpage>287</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>1</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>11</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>3</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 The Korean Neurosurgical Society</copyright-statement>
<copyright-year>2019</copyright-year>
<license>
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>The mechanistic target of rapamycin (mTOR) pathway coordinates the metabolic activity of eukaryotic cells through environmental signals, including nutrients, energy, growth factors, and oxygen. In the nervous system, the mTOR pathway regulates fundamental biological processes associated with neural development and neurodegeneration. Intriguingly, genes that constitute the mTOR pathway have been found to be germline and somatic mutation from patients with various epileptic disorders. Hyperactivation of the mTOR pathway due to said mutations has garnered increasing attention as culprits of these conditions : somatic mutations, in particular, in epileptic foci have recently been identified as a major genetic cause of intractable focal epilepsy, such as focal cortical dysplasia. Meanwhile, epilepsy models with aberrant activation of the mTOR pathway have helped elucidate the role of the mTOR pathway in epileptogenesis, and evidence from epilepsy models of human mutations recapitulating the features of epileptic patients has indicated that mTOR inhibitors may be of use in treating epilepsy associated with mutations in mTOR pathway genes. Here, we review recent advances in the molecular and genetic understanding of mTOR signaling in epileptic disorders. In particular, we focus on the development of and limitations to therapies targeting the mTOR pathway to treat epileptic seizures. We also discuss future perspectives on mTOR inhibition therapies and special diagnostic methods for intractable epilepsies caused by brain somatic mutations.</p>
</abstract>
<kwd-group>
<kwd>mTORC1</kwd>
<kwd>mTORC2</kwd>
<kwd>Epilepsy</kwd>
<kwd>Malformation of cortical development</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>The discovery of the mechanistic target of rapamycin (mTOR) began with the identification of new antimicrobial agents in soil samples from Rapa Nui (also known as Easter Island) [<xref ref-type="bibr" rid="b93-jkns-2019-0027">93</xref>]. This new antimicrobial agent, called rapamycin (clinically called sirolimus), was found to exhibit immunosuppressive and anti-cancer potential and to be of use as an antiepileptic drug [<xref ref-type="bibr" rid="b43-jkns-2019-0027">43</xref>,<xref ref-type="bibr" rid="b47-jkns-2019-0027">47</xref>,<xref ref-type="bibr" rid="b144-jkns-2019-0027">144</xref>]. For two decades, endeavors to define the function of mTOR revealed that mTOR coordinates environmental signals and metabolic activity by forming two distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) [<xref ref-type="bibr" rid="b130-jkns-2019-0027">130</xref>]. mTOR was first found in brain lysates, suggesting the importance of the brain-specific function of mTOR [<xref ref-type="bibr" rid="b125-jkns-2019-0027">125</xref>]. Indeed, the mTOR pathway has been found to regulate a variety of functions in the brain from brain development to degeneration [<xref ref-type="bibr" rid="b85-jkns-2019-0027">85</xref>].</p>
<p>Human genetic studies of epileptic patients and epilepsy models of aberrant activation of the mTOR pathway have demonstrated the importance of activating mutations in the mTOR pathway in neurodevelopmental disorders with epilepsy [<xref ref-type="bibr" rid="b66-jkns-2019-0027">66</xref>]. With the discovery of mutations activating the mTOR pathway as genetic causes of medically intractable epilepsy [<xref ref-type="bibr" rid="b4-jkns-2019-0027">4</xref>], mTOR inhibitors, such as sirolimus and everolimus, have emerged as being of potential medical use in treating intractable epilepsy patients [<xref ref-type="bibr" rid="b33-jkns-2019-0027">33</xref>]. However, with the limited efficacy and significant drawbacks of clinically available mTOR inhibitors, new drugs that are more effective and tolerable based on the understanding of pathogenic mechanisms are required. Key discoveries in research on the role of the mTOR pathway in epilepsy are summarized in <xref ref-type="supplementary-material" rid="SD1-jkns-2019-0027">Supplementary Box 1</xref>.</p>
</sec>
<sec>
<title>THE MTOR PATHWAY</title>
<p>mTOR is a serine/threonine protein kinase that forms the core subunit of two functionally distinct protein complexes : mTORC1 and mTORC2 [<xref ref-type="bibr" rid="b130-jkns-2019-0027">130</xref>] (<xref ref-type="fig" rid="f1-jkns-2019-0027">Fig. 1</xref>). mTORC1 comprises three core components : mTOR, Raptor (regulatory protein associated with mTOR), and mLST8 (mammalian lethal with Sec13 protein 8, also known as GßL) [<xref ref-type="bibr" rid="b130-jkns-2019-0027">130</xref>]. In response to environmental signals, mTORC1 acts to control the balance between anabolism and catabolism [<xref ref-type="bibr" rid="b130-jkns-2019-0027">130</xref>]. mTORC2 controls proliferation, survival, and cytoskeleton organization [<xref ref-type="bibr" rid="b130-jkns-2019-0027">130</xref>]. In a nutrient-rich environment, cells convert energy sources into macromolecules, such as proteins, lipids, and nucleotides. In nutrientstarved environments, however, cells downregulate the production of macromolecules and rely on catabolic pathways, such as autophagy, for energy.</p>
<p>The mTOR pathway receives various inputs from upstream signaling pathways in response to growth factors, amino acids, energy, oxygen, and stress [<xref ref-type="bibr" rid="b130-jkns-2019-0027">130</xref>], and the upstream pathways of mTOR can be divided as energy-sensing <italic>PI3K-PTEN-AKT-TSC</italic> and amino acid-sensing <italic>GATOR2-GATOR1-Rag</italic> GTPase pathways (<xref ref-type="fig" rid="f2-jkns-2019-0027">Fig. 2</xref>) : phosphatidylinositol-3-kinase (PI3K) is critical to integrating insulin signaling for growth and survival [<xref ref-type="bibr" rid="b130-jkns-2019-0027">130</xref>]. PTEN antagonizes the action of PI3K. Akt is activated by PI3K and is a positive regulator of mTORC1 via inhibition of Tuberous Sclerosis Complex (TSC). TSC is a heterotrimeric complex comprising TSC1, TSC2, and TBC1D7 [<xref ref-type="bibr" rid="b38-jkns-2019-0027">38</xref>]. TSC inhibits mTORC1 by acting as a GTPase activating protein for Ras homolog enriched in brain (Rheb) [<xref ref-type="bibr" rid="b67-jkns-2019-0027">67</xref>]. Rheb is a small GTPase that activates mTORC1 by directly binding to mTORC1 on the surface of lysosomes [<xref ref-type="bibr" rid="b88-jkns-2019-0027">88</xref>]. Meanwhile, Rag GTPase, a component of the amino acid sensing pathway [<xref ref-type="bibr" rid="b127-jkns-2019-0027">127</xref>], activates mTORC1 by promoting translocation of mTORC1 to the lysosomal surface. Upstream regulators of Rag GTPase in amino acid signaling are the GATOR1 and GATOR2 complexes [<xref ref-type="bibr" rid="b10-jkns-2019-0027">10</xref>]. The GATOR1 complex, consisting of DEPDC5, Nprl2, and Nprl3, inhibits the mTORC1 pathway by acting as a guanine exchange factor for Rag GTPase. The GATOR2 complex, consisting of Mios, WDR24, WDR59, Seh1L, and Sec13, is a positive regulator of the mTORC1 pathway by inhibiting GATOR1. KICSTOR, which is composed of four proteins, KPTN, ITFG2, C12orf66, and SZT2, recruits GATOR1 to the lysosome to inhibit Rag GTPase [<xref ref-type="bibr" rid="b150-jkns-2019-0027">150</xref>]. Leucyl-tRNA synthetase, which is another amino acid sensor, functions as a GTPase activating protein for Rag GTPase [<xref ref-type="bibr" rid="b57-jkns-2019-0027">57</xref>]. mTORC1 senses amino acids in an intra-lysosome fashion. Lysosomal amino acid regulates Rag GTPase via v-ATPase, which increases the guanine exchange factor activity of Ragulator towards Rag GTPase [<xref ref-type="bibr" rid="b159-jkns-2019-0027">159</xref>]. SLC38A9 is a sensor of lysosomal arginine and activates mTORC1 [<xref ref-type="bibr" rid="b69-jkns-2019-0027">69</xref>]. Additional novel mTOR upstream regulators, including a methionine sensor, have recently been discovered [<xref ref-type="bibr" rid="b1-jkns-2019-0027">1</xref>,<xref ref-type="bibr" rid="b55-jkns-2019-0027">55</xref>].</p>
<p>For macromolecule metabolism, mTORC1 regulates translation through inhibitory eukaryotic initiation factor 4E (eIF4E)-binding protein 1/2/3 (4E-BPs) and the S6 kinases (S6Ks) [<xref ref-type="bibr" rid="b21-jkns-2019-0027">21</xref>,<xref ref-type="bibr" rid="b50-jkns-2019-0027">50</xref>]. Translational control occurs predominantly at the initiation step, which commences with the binding of the eukaryotic translation initiation factor 4F (eIF4F) complex to the 5’cap [<xref ref-type="bibr" rid="b52-jkns-2019-0027">52</xref>,<xref ref-type="bibr" rid="b135-jkns-2019-0027">135</xref>]. As the limiting component of the eIF4F complex, eIF4E is considered to be a critical determinant in translation of mRNA [<xref ref-type="bibr" rid="b37-jkns-2019-0027">37</xref>]. Facilitating eIF4F formation and the progression of translation, mTORC1 phosphorylates (inactivates) the 4E-BPs, leading to their dissociation from eIF4E [<xref ref-type="bibr" rid="b51-jkns-2019-0027">51</xref>,<xref ref-type="bibr" rid="b60-jkns-2019-0027">60</xref>]. The S6Ks activate the eukaryotic translation initiation factor 4B (eIF4B), which is an activator of the eukaryotic translation initiation factor 4A, leading to an increase in the helicase activity of eIF4A and the initiation of translation [<xref ref-type="bibr" rid="b39-jkns-2019-0027">39</xref>,<xref ref-type="bibr" rid="b61-jkns-2019-0027">61</xref>].</p>
<p>Stimulating lipid synthesis, mTORC1 interacts with the sterol responsive element binding proteins transcription factors [<xref ref-type="bibr" rid="b116-jkns-2019-0027">116</xref>]. For sufficient supply of nucleotides during growth, mTORC1 promotes purine and pyrimidine nucleotide biosynthesis through MTHFD2 and the carbamoyl-phosphate synthetase [<xref ref-type="bibr" rid="b17-jkns-2019-0027">17</xref>]. Through increased translation of the HIF1α transcription factor that drives the expression of glycolytic enzymes, mTORC1 further promotes growth by changing glucose metabolism from oxidative phosphorylation to glycolysis [<xref ref-type="bibr" rid="b130-jkns-2019-0027">130</xref>]. The mTORC1 pathway also activates the transcriptional coactivator PGC1α for increased mitochondrial biosynthesis [<xref ref-type="bibr" rid="b34-jkns-2019-0027">34</xref>]. Meanwhile, mTORC1 inhibits autophagy, which plays an important role in scavenging damaged and harmful cellular structures and sustains energy homeostasis, through ULK1 [<xref ref-type="bibr" rid="b118-jkns-2019-0027">118</xref>]. Recently, it was also demonstrated that mTORC1 regulates ribosomal protein degradation through NUFIP1 [<xref ref-type="bibr" rid="b151-jkns-2019-0027">151</xref>].</p>
<p>mTORC2 largely functions as a primary effector of the insulin/PI3K signaling [<xref ref-type="bibr" rid="b130-jkns-2019-0027">130</xref>] (<xref ref-type="fig" rid="f2-jkns-2019-0027">Fig. 2</xref>). Generally, the role of the mTORC2 pathway is thought to overlap with the insulin signaling pathway, considering that phenotypes caused by perturbation of the mTORC2 pathway are very similar to those elicited by perturbation of insulin signaling [<xref ref-type="bibr" rid="b105-jkns-2019-0027">105</xref>]. Upon phosphorylation by mTORC2 [<xref ref-type="bibr" rid="b128-jkns-2019-0027">128</xref>], Akt promotes cell survival and proliferation. mTORC2 further regulates cellular proliferation and survival through the AGC (PKA/PKG/PKC) family of protein kinases.</p>
</sec>
<sec>
<title>PHYSIOLOGICAL ROLES OF THE MTOR PATHWAY IN THE BRAIN</title>
<p>The mTOR pathway plays important roles in development and aging of the central nervous system (CNS) : the mTORC1 pathway is a core regulator of neural development, cortical architecture, neuronal morphology, circuit formation, synaptic plasticity, and neurodegeneration [<xref ref-type="bibr" rid="b85-jkns-2019-0027">85</xref>]. Perturbation of the mTOR pathway has been found to disrupt several developmental processes. Defective telencephalic development was reported in mTOR mutant rats, called “flat-top” mutants [<xref ref-type="bibr" rid="b59-jkns-2019-0027">59</xref>]. The loss of function of tuberous sclerosis complex 2 (<italic>Tsc2</italic>), which is an upstream inhibitor of mTOR, was found to disrupt neuroepithelial growth [<xref ref-type="bibr" rid="b119-jkns-2019-0027">119</xref>]. Altogether, these studies demonstrated that the mTOR pathway is important for brain development by regulating neural stem cells. Meanwhile, activation of the mTOR pathway via conditional deletion of <italic>Tsc2</italic> was found to lead to the disruption of cortical layering [<xref ref-type="bibr" rid="b147-jkns-2019-0027">147</xref>]. Additionally, increased activity of the mTOR pathway due to mTOR mutations, loss of <italic>Tsc1/2</italic>, or <italic>Pten</italic>, was described as eliciting hypertrophy of soma, fewer dendritic spine, increased axon length, and increased dendritic complexity in cortical neurons [<xref ref-type="bibr" rid="b53-jkns-2019-0027">53</xref>,<xref ref-type="bibr" rid="b77-jkns-2019-0027">77</xref>,<xref ref-type="bibr" rid="b78-jkns-2019-0027">78</xref>,<xref ref-type="bibr" rid="b137-jkns-2019-0027">137</xref>,<xref ref-type="bibr" rid="b138-jkns-2019-0027">138</xref>].</p>
<p>Perturbation of the mTOR pathway has also been found to adversely affect neural circuit formation. The mTOR pathway regulates axon length [<xref ref-type="bibr" rid="b53-jkns-2019-0027">53</xref>] and axon guidance in response to environmental signals [<xref ref-type="bibr" rid="b156-jkns-2019-0027">156</xref>]. Among neurons, local protein synthesis in synapses distant from the soma is mediated by mTOR and is critical for the formation of the neural circuit. The expression levels of synaptic proteins, such as the Arc and Synapsin, are increased by activation of mTOR [<xref ref-type="bibr" rid="b81-jkns-2019-0027">81</xref>,<xref ref-type="bibr" rid="b117-jkns-2019-0027">117</xref>]. Hyperactivation of the mTOR pathway by loss of <italic>Pten</italic> has been shown to increase glutamatergic and GABAergic signals [<xref ref-type="bibr" rid="b148-jkns-2019-0027">148</xref>]. In addition to neurons, the mTOR pathway has been found to regulate glial cells during neural circuit formation. Deletion of the core component of the mTORC1 or the mTORC2, <italic>Raptor</italic> or <italic>Rictor</italic>, was reported to result in defective myelination and oligodendrocyte maturation [<xref ref-type="bibr" rid="b18-jkns-2019-0027">18</xref>,<xref ref-type="bibr" rid="b146-jkns-2019-0027">146</xref>]. Conditional <italic>Tsc1</italic> knockout in the astrocyte reportedly disrupted electrical signaling in the mouse brain by abrogating neural circuitry [<xref ref-type="bibr" rid="b141-jkns-2019-0027">141</xref>]. Interestingly, researchers have discovered crosstalk between neurons and glial cells as evidenced by a loss of myelination upon loss of TSC1 in neurons [<xref ref-type="bibr" rid="b96-jkns-2019-0027">96</xref>]. In TSC patients, the critical role of the mTOR pathway in neural circuit formation was echoed by reductions in white matter and cortical connectivity [<xref ref-type="bibr" rid="b112-jkns-2019-0027">112</xref>].</p>
<p>Neuronal synapses are crucial to storing memories. Observations of impaired memory formation and synaptic function in response to rapamycin treatment suggest the important role of the mTOR pathway in memory formation [<xref ref-type="bibr" rid="b25-jkns-2019-0027">25</xref>]. Indeed, the mTOR pathway has been found to play a crucial role in both long-term potentiation (LTP) and long-term depression (LTD) : activation of the mTOR pathway via <italic>Tsc1</italic>+/-, <italic>Tsc2</italic>+/-, or 4E-BP2 knockout (KO), results in a decrease in LTP threshold [<xref ref-type="bibr" rid="b8-jkns-2019-0027">8</xref>,<xref ref-type="bibr" rid="b41-jkns-2019-0027">41</xref>,<xref ref-type="bibr" rid="b145-jkns-2019-0027">145</xref>]. Meanwhile, reduced mTOR pathway activity disrupts LTD through metabotropic glutamate receptors (mGluRs) that disturb local protein synthesis [<xref ref-type="bibr" rid="b62-jkns-2019-0027">62</xref>,<xref ref-type="bibr" rid="b64-jkns-2019-0027">64</xref>].</p>
</sec>
<sec>
<title>ACTIVATION OF MTOR PATHWAY IN NEURODEVELOPMENTAL DISORDERS WITH EPILEPSY</title>
<p>Neurodevelopmental disorders, such as malformations of cortical development (MCD), Cowden syndrome (CS), PIK-3CA-related overgrowth spectrum (PROS), and hamartoma tumor syndromes, commonly present cortical abnormalities and are highly associated with epilepsy, developmental delay, and autism-spectrum disorders [<xref ref-type="bibr" rid="b4-jkns-2019-0027">4</xref>,<xref ref-type="bibr" rid="b12-jkns-2019-0027">12</xref>,<xref ref-type="bibr" rid="b70-jkns-2019-0027">70</xref>,<xref ref-type="bibr" rid="b80-jkns-2019-0027">80</xref>,<xref ref-type="bibr" rid="b97-jkns-2019-0027">97</xref>,<xref ref-type="bibr" rid="b106-jkns-2019-0027">106</xref>,<xref ref-type="bibr" rid="b133-jkns-2019-0027">133</xref>]. These neurodevelopmental disorders with epilepsy are a common cause of drug-resistant epilepsy in children requiring surgery for treatment [<xref ref-type="bibr" rid="b4-jkns-2019-0027">4</xref>,<xref ref-type="bibr" rid="b12-jkns-2019-0027">12</xref>]. However, about 50% of these individuals continue to experience seizures after surgical resection of the epileptic focus [<xref ref-type="bibr" rid="b94-jkns-2019-0027">94</xref>]. In addition to clinical intractability, refractory epileptic seizures also pose tremendous socioeconomic burden, based on poor quality of life, to patients and their caregivers [<xref ref-type="bibr" rid="b28-jkns-2019-0027">28</xref>].</p>
<p>Aberrant activation of the mTOR pathway has been identified in brain lesions from patients with neurodevelopmental disorders with epilepsy, especially in MCD [<xref ref-type="bibr" rid="b15-jkns-2019-0027">15</xref>,<xref ref-type="bibr" rid="b86-jkns-2019-0027">86</xref>,<xref ref-type="bibr" rid="b100-jkns-2019-0027">100</xref>]. With these results, researchers have suspected genetic mutations as culprits of the observed mTOR pathway activation in neurodevelopmental disorders [<xref ref-type="bibr" rid="b32-jkns-2019-0027">32</xref>]. Indeed, a number of neurodevelopmental disorders with epilepsy has been shown to be caused by germline or somatic mutations in the mTOR pathway : these mutations can be categorized as those affecting the energy-sensing <italic>PI3K-PTEN-AKT-TSC</italic> pathway and those affecting the amino acid-sensing <italic>GATOR2-GATOR1-Rag</italic> GTPase pathway (<xref ref-type="table" rid="t1-jkns-2019-0027">Table 1</xref>).</p>
</sec>
<sec>
<title>MUTATIONS IN THE ENERGY-SENSING <italic>PI3K-PTEN-AKT-TSC</italic> PATHWAY</title>
<p>Germline mutations in the <italic>PIK3CA</italic> gene, which activates the mTOR pathway, have been reported in CS [<xref ref-type="bibr" rid="b106-jkns-2019-0027">106</xref>]. Characterized by hamartomatous overgrowth of tissues, CS is also accompanied by epileptic seizure in a subset of patients [<xref ref-type="bibr" rid="b98-jkns-2019-0027">98</xref>,<xref ref-type="bibr" rid="b113-jkns-2019-0027">113</xref>]. There are also other brain and body overgrowth disorders with epilepsy that are caused by post-zygotic mutations in the <italic>PIK3CA</italic> pathway, which are termed PROS [<xref ref-type="bibr" rid="b70-jkns-2019-0027">70</xref>]. Additionally, mosaic or brain somatic mutations in <italic>PIK3CA</italic> have been reported in several other neurodevelopmental disorders with epilepsy, including the megalencephaly (MEG), hemimegalencephaly (HME), megalencephaly-capillary malformation (MCAP), megalencephaly-polydactyly-polymicrogyria-hydrocephalus syndromes, and focal cortical dysplasia (FCD) type IIa/IIb [<xref ref-type="bibr" rid="b36-jkns-2019-0027">36</xref>,<xref ref-type="bibr" rid="b68-jkns-2019-0027">68</xref>,<xref ref-type="bibr" rid="b79-jkns-2019-0027">79</xref>,<xref ref-type="bibr" rid="b99-jkns-2019-0027">99</xref>,<xref ref-type="bibr" rid="b122-jkns-2019-0027">122</xref>,<xref ref-type="bibr" rid="b132-jkns-2019-0027">132</xref>].</p>
<p>Classically, germline <italic>PTEN</italic> mutation has been reported in hamartoma tumor syndromes, including CS, Bannayan-Riley-Ruvalcaba syndrome, Lhermitte-Duclos disease, Proteus syndrome, and Proteus-like conditions that share the pathological phenotypes of macrocephaly and megalencephaly [<xref ref-type="bibr" rid="b97-jkns-2019-0027">97</xref>]. Epileptic seizures have been reported in patients with germline mutation in PTEN [<xref ref-type="bibr" rid="b29-jkns-2019-0027">29</xref>,<xref ref-type="bibr" rid="b30-jkns-2019-0027">30</xref>,<xref ref-type="bibr" rid="b90-jkns-2019-0027">90</xref>].</p>
<p>Brain somatic mutations in <italic>AKT3</italic> have primarily been detected in MCD, including the HME and FCD. Brain somatic gain of function mutations in <italic>AKT3</italic> were first demonstrated to cause HME [<xref ref-type="bibr" rid="b79-jkns-2019-0027">79</xref>], followed by identification of somatic <italic>AKT3</italic> mutations in FCD [<xref ref-type="bibr" rid="b68-jkns-2019-0027">68</xref>]. Germline <italic>AKT3</italic> mutations were also reported in MEG [<xref ref-type="bibr" rid="b104-jkns-2019-0027">104</xref>]. To date, germline <italic>AKT3</italic> mutations have been reported in HME, MEG, MEG with polymicrogyria, and MEG with periventricular nodular heterotopia [<xref ref-type="bibr" rid="b2-jkns-2019-0027">2</xref>].</p>
<p><italic>TSC1</italic> and <italic>TSC2</italic> germline mutations have been identified in TSC patients [<xref ref-type="bibr" rid="b142-jkns-2019-0027">142</xref>]. Brain somatic mutations in <italic>TSC1</italic> and <italic>TSC2</italic> have also been discovered in FCD type IIb [<xref ref-type="bibr" rid="b82-jkns-2019-0027">82</xref>]. Homozygous <italic>TBC1D7</italic> loss of function mutation have been identified in MEG patients [<xref ref-type="bibr" rid="b3-jkns-2019-0027">3</xref>,<xref ref-type="bibr" rid="b22-jkns-2019-0027">22</xref>]. More recently, brain somatic mutation in <italic>RHEB</italic> were identified in an HME patient [<xref ref-type="bibr" rid="b126-jkns-2019-0027">126</xref>].</p>
<p>STE20-related kinase adaptor α (STRADA) is a negative regulator of mTOR, by activating AMPK [<xref ref-type="bibr" rid="b107-jkns-2019-0027">107</xref>]. A loss-of-function mutation in STRADA was reported in autosomal recessive disease polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome, also called Pretzel syndrome (PMSE) [<xref ref-type="bibr" rid="b111-jkns-2019-0027">111</xref>].</p>
<p>Germline or mosaic mutation in <italic>MTOR</italic> has been described in the Smith-Kingsmore syndrome (SKS) OMIM #616638, which is characterized by epileptic seizure and neurodevelopmental defect [<xref ref-type="bibr" rid="b54-jkns-2019-0027">54</xref>]. SKS is a rare disease for which only 23 patients have been reported as of 2018 [<xref ref-type="bibr" rid="b54-jkns-2019-0027">54</xref>,<xref ref-type="bibr" rid="b101-jkns-2019-0027">101</xref>,<xref ref-type="bibr" rid="b102-jkns-2019-0027">102</xref>]. Brain somatic mutations in <italic>MTOR</italic> have also been described in FCD and HME, with varying degrees of mutational burden [<xref ref-type="bibr" rid="b91-jkns-2019-0027">91</xref>]. All of these mutations have been found to be missense gain-of-function mutations that activate the mTOR pathway.</p>
</sec>
<sec>
<title>MUTATIONS IN THE AMINO ACID-SENSING <italic>GATOR2-GATOR1-RAG</italic> GTPASE PATHWAY</title>
<p>Amino acid-sensing pathway is mediated by the <italic>GATOR2-GATOR1-Rag</italic> GTPase pathway. Since GATOR1 is a negative regulator of the mTORC1 pathway, researchers proposed that loss-of-function of GATOR1 would lead to neurodevelopmental disorders with epilepsy via hyperactivation of the mTORC1 pathway. Germline mutations in <italic>DEPDC5, NPRL2</italic>, and <italic>NPRL3</italic> have been reported in familial focal epilepsy with variable foci, autosomal dominant nocturnal epilepsy, temporal lobe epilepsy, and familial mesial temporal lobe epilepsy [<xref ref-type="bibr" rid="b13-jkns-2019-0027">13</xref>,<xref ref-type="bibr" rid="b121-jkns-2019-0027">121</xref>]. In addition, germline mutations in <italic>DEPDC5, NPRL2</italic>, and <italic>NPRL3</italic> have also been discovered in MCD and epileptic spasms patients [<xref ref-type="bibr" rid="b24-jkns-2019-0027">24</xref>,<xref ref-type="bibr" rid="b131-jkns-2019-0027">131</xref>,<xref ref-type="bibr" rid="b134-jkns-2019-0027">134</xref>]. Additionally, mosaicism and brain somatic mutation in GATOR1 have been reported in MCD [<xref ref-type="bibr" rid="b36-jkns-2019-0027">36</xref>], pachygyria [<xref ref-type="bibr" rid="b26-jkns-2019-0027">26</xref>] and familial focal epilepsy with focal cortical dysplasia [<xref ref-type="bibr" rid="b14-jkns-2019-0027">14</xref>]. Interestingly, it was recently demonstrated that epilepsy patients with focal cortical dysplasia carry a germline mutation in one allele of <italic>DEPDC5</italic> and a brain somatic mutation in the other allele, suggesting a two-hit hypothesis as a disease mechanism [<xref ref-type="bibr" rid="b14-jkns-2019-0027">14</xref>,<xref ref-type="bibr" rid="b120-jkns-2019-0027">120</xref>]. Autosomal recessive mutations in the KICSTOR complex, including <italic>KPTN</italic> [<xref ref-type="bibr" rid="b9-jkns-2019-0027">9</xref>,<xref ref-type="bibr" rid="b108-jkns-2019-0027">108</xref>], <italic>SZT2</italic> [<xref ref-type="bibr" rid="b11-jkns-2019-0027">11</xref>,<xref ref-type="bibr" rid="b143-jkns-2019-0027">143</xref>], and the genomic locus that contains <italic>C12orf66</italic> [<xref ref-type="bibr" rid="b95-jkns-2019-0027">95</xref>], have been identified in neurodevelopmental disorders with epilepsy. Until now, mutations in <italic>GATOR2</italic> have not been identified in epilepsy patients.</p>
</sec>
<sec>
<title>EPILEPSY ANIMAL MODELS OF HYPERACTIVATION OF THE MTOR PATHWAY</title>
<p>For extensive research into epilepsy, genetic animal models of mutations activating the mTOR pathway in epilepsy patients have been developed (<xref ref-type="table" rid="t2-jkns-2019-0027">Table 2</xref>). The first genetic model of epilepsy was the <italic>Pten</italic> KO mouse reported in 2001 [<xref ref-type="bibr" rid="b6-jkns-2019-0027">6</xref>,<xref ref-type="bibr" rid="b78-jkns-2019-0027">78</xref>]. Although Eker rats with germline mutations in the <italic>Tsc2</italic> gene were the first genetic animal model of mTOR hyperactivation, the model was not suitable for analyzing epileptic seizures due to early phase lethality [<xref ref-type="bibr" rid="b155-jkns-2019-0027">155</xref>]. In 2002, the first TSC model with epilepsy, which was the astrocyte-specific <italic>Tsc1</italic> KO model, was reported [<xref ref-type="bibr" rid="b141-jkns-2019-0027">141</xref>]; neuron-specific KO of <italic>Tsc1</italic> was also found to lead to spontaneous seizure in the mouse model [<xref ref-type="bibr" rid="b96-jkns-2019-0027">96</xref>]. After these, the <italic>Tsc2</italic> GFAP KO mouse model was developed and shown to lead to epilepsy [<xref ref-type="bibr" rid="b157-jkns-2019-0027">157</xref>]. A mouse model expressing human <italic>PI3KCA</italic> mutation in developing neural progenitors was generated to recapitulate pathological features of PROS syndrome, including epilepsy [<xref ref-type="bibr" rid="b123-jkns-2019-0027">123</xref>]. A knock-in mouse model with gain-of-function mutation in <italic>Akt3</italic> has also been found to elicit spontaneous seizure [<xref ref-type="bibr" rid="b140-jkns-2019-0027">140</xref>].</p>
<p>Recently, epilepsy models of brain somatic mutations, which recapitulate focal malformations of cortical development (FMCD), have been reported. A mouse model of FMCD was first generated by <italic>in utero</italic> electroporation, thereby providing a small portion of neurons to express known mTOR mutations in human FMCD patients [<xref ref-type="bibr" rid="b7-jkns-2019-0027">7</xref>,<xref ref-type="bibr" rid="b83-jkns-2019-0027">83</xref>,<xref ref-type="bibr" rid="b110-jkns-2019-0027">110</xref>]; these models developed spontaneous seizures. Additionally, FMCD models of brain somatic mutation in mTOR pathway genes, such as <italic>RHEB</italic> or <italic>TSC</italic>, have consistently recapitulated spontaneous seizures [<xref ref-type="bibr" rid="b63-jkns-2019-0027">63</xref>,<xref ref-type="bibr" rid="b82-jkns-2019-0027">82</xref>]. Heterozygote GATOR1 gene (<italic>Depdc5, Nprl2</italic>, and <italic>Nprl3</italic>) KO animals have not been found to recapitulate epileptic seizures observed in patients with germline mutations in the GATOR1 genes [<xref ref-type="bibr" rid="b40-jkns-2019-0027">40</xref>,<xref ref-type="bibr" rid="b65-jkns-2019-0027">65</xref>,<xref ref-type="bibr" rid="b72-jkns-2019-0027">72</xref>,<xref ref-type="bibr" rid="b92-jkns-2019-0027">92</xref>]. Interestingly, FMCD mouse model caused by a biallelic two-hit mutation (brain somatic and germline) in <italic>Depdc5</italic> was shown to lead to spontaneous seizure [<xref ref-type="bibr" rid="b120-jkns-2019-0027">120</xref>]. Homozygous KO of <italic>Szt2</italic>, a component of the KICSTOR complex, has been reported as leading to low seizure threshold in mice [<xref ref-type="bibr" rid="b46-jkns-2019-0027">46</xref>].</p>
</sec>
<sec>
<title>MTOR PATHWAY ACTIVATION IN EPILEPTOGENESIS</title>
<p>Epileptogenesis refers to the process leading to the first spontaneous seizure after pro-epileptogenic insult (e.g., genetic defect, brain injury, status epilepticus, or cancer). Epileptogenesis is a brain-wide circuit rewiring process comprising reorganization of microcircuits to long-range circuits, as well as gliosis, blood-brain barrier damage, inflammation, and neurodegeneration [<xref ref-type="bibr" rid="b114-jkns-2019-0027">114</xref>].</p>
<p>Since epilepsy is the consequence of electrical changes, electrophysiological characteristics in animal models and epilepsy patients have been analyzed in an attempt to understand the epileptogenic mechanism. Studies have indicated that highfrequency oscillations on electroencephalogram are characteristic of FCD [<xref ref-type="bibr" rid="b20-jkns-2019-0027">20</xref>]. Organotypic brain slice analysis of resected FCD lesions has revealed an electrographic firing pattern of ictal-like discharges after 4-aminopyridine treatment [<xref ref-type="bibr" rid="b5-jkns-2019-0027">5</xref>], which decreased with treatment with GABAA receptor antagonist.</p>
<p>In brain slice cultures of hyperactive mTOR signaling, researchers have found both the frequency and amplitude of the miniature excitatory postsynaptic current to be increased in glutamatergic synaptic transmission of the hippocampus [<xref ref-type="bibr" rid="b89-jkns-2019-0027">89</xref>,<xref ref-type="bibr" rid="b138-jkns-2019-0027">138</xref>]. In GABAergic neurons, hyperactive mTOR signaling increased evoked synaptic responses in the hippocampus [<xref ref-type="bibr" rid="b148-jkns-2019-0027">148</xref>]. In a subset of auditory cortical neurons of <italic>Pten</italic> conditional KO, synaptic inputs from the long-range connections, including the contralateral auditory cortex and thalamus, and local connections were increased [<xref ref-type="bibr" rid="b152-jkns-2019-0027">152</xref>].</p>
<p>In an epilepsy animal model of brain somatic mutations in the mTOR pathway, mutation-carrying cortical neurons showed an increased capacitance, increased cell size, reduced input resistance indicative of a higher current needed to reach the voltage threshold of the action potential, and increased gain of firing frequency [<xref ref-type="bibr" rid="b120-jkns-2019-0027">120</xref>]. Also, spontaneous excitatory postsynaptic current frequency was decreased in the mTOR pathway mutation-carrying cortical neurons [<xref ref-type="bibr" rid="b84-jkns-2019-0027">84</xref>,<xref ref-type="bibr" rid="b120-jkns-2019-0027">120</xref>].</p>
<p>There have been tremendous advances in the identification of the contribution of mTOR downstream functions to neuronal hypertrophy, dendritic branching, axon length, and neuronal migration. Although numerous epilepsy animal models have been utilized to unravel the path to epileptogenesis, the downstream mechanism of mTOR signaling that accounts for epileptogenesis remains unclear. The complexity of the downstream output of the mTOR pathway has hampered attempts to understand the epileptogenic mechanism. Using genetic manipulation techniques, normalizing major downstream outputs of hyperactive mTOR signaling, including translation via overexpressing constitutively active 4E-BP or knockdown of S6Ks [<xref ref-type="bibr" rid="b84-jkns-2019-0027">84</xref>] and autophagy via knockdown of OFD1 [<xref ref-type="bibr" rid="b110-jkns-2019-0027">110</xref>], have failed to prevent or even reduce epileptogenesis. Further studies defining the downstream pathway of mTOR in epileptogenesis will be necessary.</p>
</sec>
<sec>
<title>INHIBITION OF THE MTOR PATHWAY IN TREATMENT OF EPILEPTIC DISORDERS</title>
<p>Researchers have hypothesized that epilepsy resulting from mTOR pathway activation could be treated by mTOR inhibition, and mTOR inhibition therapies have been evaluated in several clinical trials for epilepsy (<xref ref-type="table" rid="t3-jkns-2019-0027">Table 3</xref>). Rapalogs, including sirolimus and everolimus, have been reported as promising new anti-epileptics because they can penetrate the blood brain-barrier [<xref ref-type="bibr" rid="b71-jkns-2019-0027">71</xref>]. Rapalogs have been extensively tested and have gained the US Food and Drug Administration (FDA) approval as anti-epileptics in TSC [<xref ref-type="bibr" rid="b27-jkns-2019-0027">27</xref>,<xref ref-type="bibr" rid="b47-jkns-2019-0027">47</xref>,<xref ref-type="bibr" rid="b73-jkns-2019-0027">73</xref>].</p>
<p>The first study to show the beneficial effect of the rapalogs on epilepsy did so in a mouse model of TSC [<xref ref-type="bibr" rid="b158-jkns-2019-0027">158</xref>]. In this study, early treatment with sirolimus prevented the development of epilepsy. The anti-epileptic effect of rapalogs has also been demonstrated in other genetic models of epilepsy with mTOR pathway hyperactivation, including <italic>Pten</italic> [<xref ref-type="bibr" rid="b87-jkns-2019-0027">87</xref>] KO and <italic>Strada</italic> KO [<xref ref-type="bibr" rid="b111-jkns-2019-0027">111</xref>]. Recently, intractable epilepsy mouse models with brain somatic mutation in the mTOR pathway were found to be cured by rapalogs [<xref ref-type="bibr" rid="b63-jkns-2019-0027">63</xref>,<xref ref-type="bibr" rid="b82-jkns-2019-0027">82</xref>,<xref ref-type="bibr" rid="b83-jkns-2019-0027">83</xref>]. Interestingly, epileptic seizure was almost completely suppressed by mTOR inhibitors in mouse models of TSC KO or mTOR activating mutation, but only partially suppressed in <italic>Pten</italic> KO mouse models [<xref ref-type="bibr" rid="b87-jkns-2019-0027">87</xref>]. These results suggest that an independent mechanism of epileptogenesis distinct from that in TSC KO or mTOR mutation is present in the Pten KO model. In nongenetic seizure models, including the pilocarpine-induced epilepsy model, kainic acid-induced epilepsy model, and absence epilepsy model, rapalogs partially reduced seizures. Citraro et al. [<xref ref-type="bibr" rid="b31-jkns-2019-0027">31</xref>] reported a representative studies of the anti-epileptic effect of rapalogs in an animal model of intractable epilepsy.</p>
<p>Everolimus have been approved by the FDA for treating subependymal giant astrocytoma, kidney tumors, and partial epilepsy in TSC patients. The first trial to test the efficacy of everolimus to treat epileptic seizure was reported in 2010 for TSC patients [<xref ref-type="bibr" rid="b74-jkns-2019-0027">74</xref>]. In this study, seizure frequency was reduced in nine of 16 patients with everolimus. Following studies supported the anti-epileptic effects of everolimus or sirolimus (<xref ref-type="table" rid="t3-jkns-2019-0027">Table 3</xref>).</p>
<p>The prospective, randomized, multicenter, placebo-controlled study testing the seizure suppression effect of everolimus on seizure frequency in TSC patients with drug-resistant epilepsy reported positive results [<xref ref-type="bibr" rid="b49-jkns-2019-0027">49</xref>]. Recently, long-term results of the prospective, open-label, non-randomized study of everolimus for treating epileptic seizure in TSC indicated that reduction in seizure frequency is sustained for up to 4 years [<xref ref-type="bibr" rid="b75-jkns-2019-0027">75</xref>]. This effect has been confirmed in the long-term follow-up of the EXIST3 trial [<xref ref-type="bibr" rid="b35-jkns-2019-0027">35</xref>]. Large-scale studies on the anti-epileptic effect of everolimus have described response rates for everolimus and a median seizure frequency reduction in respondents of about 40% [<xref ref-type="bibr" rid="b35-jkns-2019-0027">35</xref>,<xref ref-type="bibr" rid="b75-jkns-2019-0027">75</xref>]. In 2017 and 2018, respectively, both the European Medicinal Agency in Europe and the US FDA approved everolimus as an adjunctive therapy in partial-onset seizures in TSC patients aged 2 years and older. However, there are reports of non-responders, seizure aggravation, or an withdrawal after everolimus administration [<xref ref-type="bibr" rid="b35-jkns-2019-0027">35</xref>,<xref ref-type="bibr" rid="b149-jkns-2019-0027">149</xref>]. Meanwhile, clinical trials for treating epileptic seizure in FCD type II with everolimus have recently started (clinicaltrials.gov identifier NCT03198949).</p>
<p>The first report of the anti-epileptic effect of sirolimus in TSC patients, which appears to be similar to that of everolimus [<xref ref-type="bibr" rid="b23-jkns-2019-0027">23</xref>], was in 2009 [<xref ref-type="bibr" rid="b103-jkns-2019-0027">103</xref>]. In HME patients with brain somatic mutation in mTOR, sirolimus administration reduced seizures [<xref ref-type="bibr" rid="b153-jkns-2019-0027">153</xref>]. Interestingly, sirolimus has been shown to prevent epilepsy in PMSE patients [<xref ref-type="bibr" rid="b111-jkns-2019-0027">111</xref>].</p>
<p>Animal and human treatment studies reported that withdrawal of rapalogs provokes seizure recurrence [<xref ref-type="bibr" rid="b73-jkns-2019-0027">73</xref>]. In electrophysiological analysis of brain slices of resected epileptic foci, everolimus was found to reduce spontaneous excitatory postsynaptic activity, burst discharges, and epileptiform activity in TSC, FCD, and HME cases; effects were subtle in epilepsy patients without mTOR mutations [<xref ref-type="bibr" rid="b27-jkns-2019-0027">27</xref>].</p>
<p>While rapalogs have been approved for use in various human diseases, concerns have been raised for their long-term use and their adverse effect profile, including potentially serious adverse effects. The adverse effects of rapalogs include immunosuppression, mucositis, hyperlipidemia, hyperglycemia, diabetes-like syndrome, and fatal pneumonitis [<xref ref-type="bibr" rid="b42-jkns-2019-0027">42</xref>,<xref ref-type="bibr" rid="b76-jkns-2019-0027">76</xref>,<xref ref-type="bibr" rid="b109-jkns-2019-0027">109</xref>,<xref ref-type="bibr" rid="b139-jkns-2019-0027">139</xref>]. In a phase III clinical trial with everolimus, over 90% of 111 patients experienced an adverse effects of any grade [<xref ref-type="bibr" rid="b48-jkns-2019-0027">48</xref>]. With everolimus treatment for over 1 year, grade 3 or 4 adverse events, which are severe adverse events, were reported in 45% of younger patients and 38% of older patients among 150 patients [<xref ref-type="bibr" rid="b35-jkns-2019-0027">35</xref>]. We should stress that developmental delay caused by rapalogs [<xref ref-type="bibr" rid="b63-jkns-2019-0027">63</xref>] should be a concern, considering that the onset of intractable epilepsy with mTOR pathway mutation is usually before adolescence [<xref ref-type="bibr" rid="b4-jkns-2019-0027">4</xref>]. Additionally, treatment with rapalogs has been found to induce adverse nervous system-specific effects altering sociability [<xref ref-type="bibr" rid="b129-jkns-2019-0027">129</xref>], learning and memory [<xref ref-type="bibr" rid="b16-jkns-2019-0027">16</xref>,<xref ref-type="bibr" rid="b25-jkns-2019-0027">25</xref>], and anxiety [<xref ref-type="bibr" rid="b56-jkns-2019-0027">56</xref>] in mouse models.</p>
<p>For epilepsy caused by brain somatic mutations, therapeutic regimens must seek to avoid perturbations outside of the CNS, and in this regard, antisense oligonucleotide (ASO) drugs appear to be promising therapeutic options. ASO is a complementary oligonucleotide sequence of sense mRNA sequences that hampers normal gene expression processes, including splicing, transcription, and translation [<xref ref-type="bibr" rid="b136-jkns-2019-0027">136</xref>]. The characteristics of the bloodbrain barrier prevent ASO from permeating outside of the CNS when administered into the cerebrospinal fluid via intrathecal injection. Moreover, the half-life of ASO drugs is more than 3 months [<xref ref-type="bibr" rid="b19-jkns-2019-0027">19</xref>]. Recently, ASO drugs have been approved by the FDA for treating various types of neurodegenerative disorders [<xref ref-type="bibr" rid="b45-jkns-2019-0027">45</xref>]. We suspect that intrathecal injection of ASO drugs targeting mTOR itself, mTOR mutation, or downstream targets of mTOR will prove effective in treating intractable epilepsies while avoiding the adverse effects of rapalogs outside of the CNS.</p>
</sec>
<sec sec-type="conclusions">
<title>CONCLUSION</title>
<p>Over the last two decades, extensive research to outline the roles of the mTOR pathway, to identify mutations in the mTOR pathway in human epilepsy patients, and to develop mTOR inhibitors have led to the discovery of novel strategies for diagnosing and treating intractable epilepsy. The overarching goal of this clinical research is attaining seizure-free status with few to no adverse effects in epilepsy patients. While rapalogs have proven to be effective in controlling seizures, complete seizure cessation has not been recorded in most of patients [<xref ref-type="bibr" rid="b35-jkns-2019-0027">35</xref>,<xref ref-type="bibr" rid="b75-jkns-2019-0027">75</xref>]. Also, about half of all TSC patients fail to respond to rapalogs. These discrepancies suggest that there might be an unknown biological mechanism at play. Considering about 40% of patients treated with rapalogs experience a severe adverse effect, it will be necessary to develop more potent and tolerable therapies.</p>
<p>While FMCD patients with drug-resistant epilepsy typically undergo surgical resection of the epileptic focus for treating the seizure, up to 50% of patients do not respond to therapy. Based on preclinical and clinical studies of TSC with rapalogs, it may no longer be necessary to perform highly invasive surgical resection for seizure treatment. However, there is a problem in that diagnosing FMCD patients with low-frequency brain somatic mutation in the mTOR pathway requires analyzing DNA from brain tissue after surgical resection. To alleviate this issue, minimally invasive diagnosis through biomarkers in patient cerebrospinal fluid would prove invaluable.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="COI-statement">
<p>J.H.L is a co-founder of SoVarGen, Inc. that develops new diagnostics and therapeutics for brain disorders. The remaining authors declare no competing financial interests.</p>
</fn>
<fn>
<p>INFORMED CONSENT</p>
<p>Informed consent was obtained from all individual participants included in this study.</p>
</fn>
</fn-group>
<ack>
<p>This work was supported by grants from the Suh Kyungbae Foundation (to J.H.L.), Korean Health Technology R&amp;D Project, Ministry of Health &amp; Welfare, Republic of Korea (H15C3143 and H16C0415 to J.H.L.), and Cheong-Am Science Fellow supported by POSCO Cheong-Am Foundation (to J.K.K).</p>
</ack>
<sec sec-type="supplementary-material">
<title>Supplementary Materials</title>
<p>The online-only data supplement is available with this article at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3340/jkns.2019.0027">https://doi.org/10.3340/jkns.2019.0027</ext-link>.</p>
<supplementary-material content-type="local-data" id="SD1-jkns-2019-0027">
<label>Supplementary Box 1.</label>
<caption>
<p>Key discoveries in research on the role of the mTOR pathway in epilepsy.</p>
</caption>
<media id="d35e1122" mime-subtype="pdf" mimetype="application" orientation="portrait" position="anchor" xlink:href="jkns-2019-0027-suppl.pdf"></media>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-jkns-2019-0027">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abu-Remaileh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wyant</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Laqtom</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Abbasi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>SH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from lysosomes</article-title>
<source/>Science
          <volume>358</volume>
<fpage>807</fpage>
<lpage>813</lpage>
<year>2017</year>
<pub-id pub-id-type="pmid">29074583</pub-id>
</element-citation>
</ref>
<ref id="b2-jkns-2019-0027">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alcantara</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Timms</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Gripp</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations of AKT3 are associated with a wide spectrum of developmental disorders including extreme megalencephaly</article-title>
<source/>Brain
          <volume>140</volume>
<fpage>2610</fpage>
<lpage>2622</lpage>
<year>2017</year>
<pub-id pub-id-type="pmid">28969385</pub-id>
</element-citation>
</ref>
<ref id="b3-jkns-2019-0027">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alfaiz</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Micale</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mandriani</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Augello</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pellico</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Chrast</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TBC1D7 mutations are associated with intellectual disability, macrocrania, patellar dislocation, and celiac disease</article-title>
<source/>Hum Mutat
          <volume>35</volume>
<fpage>447</fpage>
<lpage>451</lpage>
<year>2014</year>
<pub-id pub-id-type="pmid">24515783</pub-id>
</element-citation>
</ref>
<ref id="b4-jkns-2019-0027">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aronica</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Spreafico</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Malformations of cortical development</article-title>
<source/>Brain Pathol
          <volume>22</volume>
<fpage>380</fpage>
<lpage>401</lpage>
<year>2012</year>
<pub-id pub-id-type="pmid">22497611</pub-id>
</element-citation>
</ref>
<ref id="b5-jkns-2019-0027">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Avoli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bernasconi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mattia</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Olivier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hwa</surname>
<given-names>GG</given-names>
</name>
</person-group>
<article-title>Epileptiform discharges in the human dysplastic neocortex: in vitro physiology and pharmacology</article-title>
<source/>Ann Neurol
          <volume>46</volume>
<fpage>816</fpage>
<lpage>826</lpage>
<year>1999</year>
<pub-id pub-id-type="pmid">10589533</pub-id>
</element-citation>
</ref>
<ref id="b6-jkns-2019-0027">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Backman</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Stambolic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Haight</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Elia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pretorius</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease</article-title>
<source/>Nat Genet
          <volume>29</volume>
<fpage>396</fpage>
<lpage>403</lpage>
<year>2001</year>
<pub-id pub-id-type="pmid">11726926</pub-id>
</element-citation>
</ref>
<ref id="b7-jkns-2019-0027">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baek</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Copeland</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Guemez-Gamboa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schaffer</surname>
<given-names>AE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An AKT3-FOXG1-reelin network underlies defective migration in human focal malformations of cortical development</article-title>
<source/>Nat Med
          <volume>21</volume>
<fpage>1445</fpage>
<lpage>1454</lpage>
<year>2015</year>
<pub-id pub-id-type="pmid">26523971</pub-id>
</element-citation>
</ref>
<ref id="b8-jkns-2019-0027">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banko</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Poulin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>DeMaria</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Sonenberg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Klann</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus</article-title>
<source/>J Neurosci
          <volume>25</volume>
<fpage>9581</fpage>
<lpage>9590</lpage>
<year>2005</year>
<pub-id pub-id-type="pmid">16237163</pub-id>
</element-citation>
</ref>
<ref id="b9-jkns-2019-0027">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baple</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Maroofian</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chioza</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Izadi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Al-Turki</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in KPTN cause macrocephaly, neurodevelopmental delay, and seizures</article-title>
<source/>Am J Hum Genet
          <volume>94</volume>
<fpage>87</fpage>
<lpage>94</lpage>
<year>2014</year>
<pub-id pub-id-type="pmid">24239382</pub-id>
</element-citation>
</ref>
<ref id="b10-jkns-2019-0027">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bar-Peled</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schweitzer</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Zoncu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1</article-title>
<source/>Cell
          <volume>150</volume>
<fpage>1196</fpage>
<lpage>1208</lpage>
<year>2012</year>
<pub-id pub-id-type="pmid">22980980</pub-id>
</element-citation>
</ref>
<ref id="b11-jkns-2019-0027">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basel-Vanagaite</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hershkovitz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Heyman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Raspall-Chaure</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kakar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Smirin-Yosef</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum</article-title>
<source/>Am J Hum Genet
          <volume>93</volume>
<fpage>524</fpage>
<lpage>529</lpage>
<year>2013</year>
<pub-id pub-id-type="pmid">23932106</pub-id>
</element-citation>
</ref>
<ref id="b12-jkns-2019-0027">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bast</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ramantani</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Seitz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rating</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Focal cortical dysplasia: prevalence, clinical presentation and epilepsy in children and adults</article-title>
<source/>Acta Neurol Scand
          <volume>113</volume>
<fpage>72</fpage>
<lpage>81</lpage>
<year>2006</year>
<pub-id pub-id-type="pmid">16411966</pub-id>
</element-citation>
</ref>
<ref id="b13-jkns-2019-0027">
<label>13</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Baulac</surname>
<given-names>S</given-names>
</name>
</person-group>
<chapter-title>MTOR signaling pathway genes in focal epilepsies</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>Rossignol</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Carmant</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lacaille</surname>
<given-names>JC</given-names>
</name>
</person-group>
<source/>Progress in Brain Research
          <publisher-loc>Amsterdam</publisher-loc>
<publisher-name>Elsevier</publisher-name>
<year>2016</year>
<volume>226</volume>
<fpage>61</fpage>
<lpage>79</lpage>
</element-citation>
</ref>
<ref id="b14-jkns-2019-0027">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baulac</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ishida</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marsan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Miquel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Biraben</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>DK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations</article-title>
<source/>Ann Neurol
          <volume>77</volume>
<fpage>675</fpage>
<lpage>683</lpage>
<year>2015</year>
<pub-id pub-id-type="pmid">25623524</pub-id>
</element-citation>
</ref>
<ref id="b15-jkns-2019-0027">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baybis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Golden</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Weiner</surname>
<given-names>H</given-names>
</name>
<name>
<surname>McKhann G</surname>
<given-names>2nd</given-names>
</name>
<etal></etal>
</person-group>
<article-title>mTOR cascade activation distinguishes tubers from focal cortical dysplasia</article-title>
<source/>Ann Neurol
          <volume>56</volume>
<fpage>478</fpage>
<lpage>487</lpage>
<year>2004</year>
<pub-id pub-id-type="pmid">15455405</pub-id>
</element-citation>
</ref>
<ref id="b16-jkns-2019-0027">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beaumont</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fletcher</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Froemke</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Zucker</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Phosphorylation and local presynaptic protein synthesis in calcium- and calcineurindependent induction of crayfish long-term facilitation</article-title>
<source/>Neuron
          <volume>32</volume>
<fpage>489</fpage>
<lpage>501</lpage>
<year>2001</year>
<pub-id pub-id-type="pmid">11709159</pub-id>
</element-citation>
</ref>
<ref id="b17-jkns-2019-0027">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ben-Sahra</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Howell</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Asara</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Manning</surname>
<given-names>BD</given-names>
</name>
</person-group>
<article-title>Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1</article-title>
<source/>Science
          <volume>339</volume>
<fpage>1323</fpage>
<lpage>1328</lpage>
<year>2013</year>
<pub-id pub-id-type="pmid">23429703</pub-id>
</element-citation>
</ref>
<ref id="b18-jkns-2019-0027">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bercury</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sachs</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Ahrendsen</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Macklin</surname>
<given-names>WB</given-names>
</name>
</person-group>
<article-title>Conditional ablation of raptor or rictor has differential impact on oligodendrocyte differentiation and CNS myelination</article-title>
<source/>J Neurosci
          <volume>34</volume>
<fpage>4466</fpage>
<lpage>4480</lpage>
<year>2014</year>
<pub-id pub-id-type="pmid">24671993</pub-id>
</element-citation>
</ref>
<ref id="b19-jkns-2019-0027">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bishop</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases</article-title>
<source/>Neuropharmacology
          <volume>120</volume>
<fpage>56</fpage>
<lpage>62</lpage>
<year>2017</year>
<pub-id pub-id-type="pmid">27998711</pub-id>
</element-citation>
</ref>
<ref id="b20-jkns-2019-0027">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blümcke</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Neuropathology of focal epilepsies: a critical review</article-title>
<source/>Epilepsy Behav
          <volume>15</volume>
<fpage>34</fpage>
<lpage>39</lpage>
<year>2009</year>
<pub-id pub-id-type="pmid">19248840</pub-id>
</element-citation>
</ref>
<ref id="b21-jkns-2019-0027">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Beal</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Keith</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>SL</given-names>
</name>
</person-group>
<article-title>Control of p70 S6 kinase by kinase activity of FRAP in vivo</article-title>
<source/>Nature
          <volume>377</volume>
<fpage>441</fpage>
<lpage>446</lpage>
<year>1995</year>
<pub-id pub-id-type="pmid">7566123</pub-id>
</element-citation>
</ref>
<ref id="b22-jkns-2019-0027">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Capo-Chichi</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Tcherkezian</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hamdan</surname>
<given-names>FF</given-names>
</name>
<name>
<surname>Décarie</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Dobrzeniecka</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Patry</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disruption of TBC1D7, a subunit of the TSC1-TSC2 protein complex, in intellectual disability and megalencephaly</article-title>
<source/>J Med Genet
          <volume>50</volume>
<fpage>740</fpage>
<lpage>744</lpage>
<year>2013</year>
<pub-id pub-id-type="pmid">23687350</pub-id>
</element-citation>
</ref>
<ref id="b23-jkns-2019-0027">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardamone</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Flanagan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mowat</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Chopra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex</article-title>
<source/>J Pediatr
          <volume>164</volume>
<fpage>1195</fpage>
<lpage>1200</lpage>
<year>2014</year>
<pub-id pub-id-type="pmid">24518170</pub-id>
</element-citation>
</ref>
<ref id="b24-jkns-2019-0027">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carvill</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Crompton</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Regan</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Saykally</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zemel</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epileptic spasms are a feature of DEPDC5 mTORopathy</article-title>
<source/>Neurol Genet
          <volume>1</volume>
<fpage>e17</fpage>
<year>2015</year>
<pub-id pub-id-type="pmid">27066554</pub-id>
</element-citation>
</ref>
<ref id="b25-jkns-2019-0027">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casadio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Giustetto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bartsch</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A transient, neuron-wide form of creb-mediated long-term facilitation can be stabilized at specific synapses by local protein synthesis</article-title>
<source/>Cell
          <volume>99</volume>
<fpage>221</fpage>
<lpage>237</lpage>
<year>1999</year>
<pub-id pub-id-type="pmid">10535740</pub-id>
</element-citation>
</ref>
<ref id="b26-jkns-2019-0027">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>De novo mutation in DEPDC5 associated with unilateral pachygyria and intractable epilepsy</article-title>
<source/>Seizure
          <volume>50</volume>
<fpage>1</fpage>
<lpage>3</lpage>
<year>2017</year>
<pub-id pub-id-type="pmid">28549235</pub-id>
</element-citation>
</ref>
<ref id="b27-jkns-2019-0027">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cepeda</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Levinson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yazon</surname>
<given-names>VW</given-names>
</name>
<name>
<surname>Barry</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mathern</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Fallah</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cellular antiseizure mechanisms of everolimus in pediatric tuberous sclerosis complex, cortical dysplasia, and non-mTOR-mediated etiologies</article-title>
<source/>Epilepsia Open
          <volume>3</volume>
<issue>Suppl Suppl 2</issue>
<fpage>180</fpage>
<lpage>190</lpage>
<year>2018</year>
<pub-id pub-id-type="pmid">30564777</pub-id>
</element-citation>
</ref>
<ref id="b28-jkns-2019-0027">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>TR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cognitive and epilepsy outcomes after epilepsy surgery caused by focal cortical dysplasia in children: early intervention maybe better</article-title>
<source/>Child’s Nerv Syst
          <volume>30</volume>
<fpage>1885</fpage>
<lpage>1895</lpage>
<year>2014</year>
<pub-id pub-id-type="pmid">25296550</pub-id>
</element-citation>
</ref>
<ref id="b29-jkns-2019-0027">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheung</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Siu</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Yong</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Atypical focal cortical dysplasia in a patient with Cowden syndrome</article-title>
<source/>Hong Kong Med J
          <volume>20</volume>
<fpage>165</fpage>
<lpage>167</lpage>
<year>2014</year>
<pub-id pub-id-type="pmid">24714173</pub-id>
</element-citation>
</ref>
<ref id="b30-jkns-2019-0027">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Child</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Cascino</surname>
<given-names>GD</given-names>
</name>
</person-group>
<article-title>Mystery case: Cowden syndrome presenting with partial epilepsy related to focal cortical dysplasia</article-title>
<source/>Neurology
          <volume>81</volume>
<fpage>e98</fpage>
<lpage>e99</lpage>
<year>2013</year>
<pub-id pub-id-type="pmid">24062348</pub-id>
</element-citation>
</ref>
<ref id="b31-jkns-2019-0027">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Citraro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Leo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Constanti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>De Sarro</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis</article-title>
<source/>Pharmacol Res
          <volume>107</volume>
<fpage>333</fpage>
<lpage>343</lpage>
<year>2016</year>
<pub-id pub-id-type="pmid">27049136</pub-id>
</element-citation>
</ref>
<ref id="b32-jkns-2019-0027">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crino</surname>
<given-names>PB</given-names>
</name>
</person-group>
<article-title>Focal brain malformations: a spectrum of disorders along the mTOR cascade</article-title>
<source/>Novartis Found Smyp
          <volume>288</volume>
<fpage>260</fpage>
<lpage>272</lpage>
<comment>discussion 272-281</comment>
<year>2007</year>
</element-citation>
</ref>
<ref id="b33-jkns-2019-0027">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crino</surname>
<given-names>PB</given-names>
</name>
</person-group>
<article-title>The mTOR signalling cascade: paving new roads to cure neurological disease</article-title>
<source/>Nat Rev Neurol
          <volume>12</volume>
<fpage>379</fpage>
<lpage>392</lpage>
<year>2016</year>
<pub-id pub-id-type="pmid">27340022</pub-id>
</element-citation>
</ref>
<ref id="b34-jkns-2019-0027">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunningham</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Rodgers</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Arlow</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Vazquez</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mootha</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Puigserver</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>mTOR controls mitochondrial oxidative function through a YY1-PGC-1a transcriptional complex</article-title>
<source/>Nature
          <volume>450</volume>
<fpage>736</fpage>
<lpage>740</lpage>
<year>2007</year>
<pub-id pub-id-type="pmid">18046414</pub-id>
</element-citation>
</ref>
<ref id="b35-jkns-2019-0027">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Yapici</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Polster</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adjunctive everolimus for children and adolescents with treatmentrefractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial</article-title>
<source/>Lancet Child Adolesc Health
          <volume>2</volume>
<fpage>495</fpage>
<lpage>504</lpage>
<year>2018</year>
<pub-id pub-id-type="pmid">30169322</pub-id>
</element-citation>
</ref>
<ref id="b36-jkns-2019-0027">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Gama</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Couto</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Boyle</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>LaCoursiere</surname>
<given-names>CM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia</article-title>
<source/>Ann Neurol
          <volume>77</volume>
<fpage>720</fpage>
<lpage>725</lpage>
<year>2015</year>
<pub-id pub-id-type="pmid">25599672</pub-id>
</element-citation>
</ref>
<ref id="b37-jkns-2019-0027">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Benedetti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Joshi-Barve</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rinker-Schaeffer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rhoads</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F</article-title>
<source/>Mol Cell Biol
          <volume>11</volume>
<fpage>5435</fpage>
<lpage>5445</lpage>
<year>1991</year>
<pub-id pub-id-type="pmid">1922056</pub-id>
</element-citation>
</ref>
<ref id="b38-jkns-2019-0027">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dibble</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Elis</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Menon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Klekota</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Asara</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1</article-title>
<source/>Mol Cell
          <volume>47</volume>
<fpage>535</fpage>
<lpage>546</lpage>
<year>2012</year>
<pub-id pub-id-type="pmid">22795129</pub-id>
</element-citation>
</ref>
<ref id="b39-jkns-2019-0027">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dorrello</surname>
<given-names>NV</given-names>
</name>
<name>
<surname>Peschiaroli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guardavaccaro</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Colburn</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Pagano</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>S6K1- and ßTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth</article-title>
<source/>Science
          <volume>314</volume>
<fpage>467</fpage>
<lpage>471</lpage>
<year>2006</year>
<pub-id pub-id-type="pmid">17053147</pub-id>
</element-citation>
</ref>
<ref id="b40-jkns-2019-0027">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dutchak</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Laxman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Estill</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Regulation of hematopoiesis and methionine homeostasis by mTORC1 inhibitor NPRL2</article-title>
<source/>Cell Rep
          <volume>12</volume>
<fpage>371</fpage>
<lpage>379</lpage>
<year>2015</year>
<pub-id pub-id-type="pmid">26166573</pub-id>
</element-citation>
</ref>
<ref id="b41-jkns-2019-0027">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ehninger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shilyansky</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kwiatkowski</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis</article-title>
<source/>Nat Med
          <volume>14</volume>
<fpage>843</fpage>
<lpage>848</lpage>
<year>2008</year>
<pub-id pub-id-type="pmid">18568033</pub-id>
</element-citation>
</ref>
<ref id="b42-jkns-2019-0027">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eisen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mulders</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pyle</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zbinden</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeted therapies for renal cell carcinoma: review of adverse event management strategies</article-title>
<source/>J Natl Cancer Inst
          <volume>104</volume>
<fpage>93</fpage>
<lpage>113</lpage>
<year>2012</year>
<pub-id pub-id-type="pmid">22235142</pub-id>
</element-citation>
</ref>
<ref id="b43-jkns-2019-0027">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eng</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Sehgal</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Vézina</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Activity of rapamycin (AY-22,989) against transplanted tumors</article-title>
<source/>J Antibiot (Tokyo)
          <volume>37</volume>
<fpage>1231</fpage>
<lpage>1237</lpage>
<year>1984</year>
<pub-id pub-id-type="pmid">6501094</pub-id>
</element-citation>
</ref>
<ref id="b44-jkns-2019-0027">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>European Chromosome 16 Tuberous Sclerosis Consortium</collab>
</person-group>
<article-title>Identification and characterization of the tuberous sclerosis gene on chromosome 16</article-title>
<source/>Cell
          <volume>75</volume>
<fpage>1305</fpage>
<lpage>15</lpage>
<year>1993</year>
<pub-id pub-id-type="pmid">8269512</pub-id>
</element-citation>
</ref>
<ref id="b45-jkns-2019-0027">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finkel</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Mercuri</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Darras</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Connolly</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Kuntz</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Kirschner</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nusinersen versus sham control in infantile-onset spinal muscular atrophy</article-title>
<source/>N Engl J Med
          <volume>337</volume>
<fpage>1723</fpage>
<lpage>1732</lpage>
<year>2017</year>
</element-citation>
</ref>
<ref id="b46-jkns-2019-0027">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frankel</surname>
<given-names>WN</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mahaffey</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Beyer</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>TP</given-names>
</name>
</person-group>
<article-title>Szt2, a novel gene for seizure threshold in mice</article-title>
<source/>Genes Brain Behav
          <volume>8</volume>
<fpage>568</fpage>
<lpage>576</lpage>
<year>2009</year>
<pub-id pub-id-type="pmid">19624305</pub-id>
</element-citation>
</ref>
<ref id="b47-jkns-2019-0027">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Agricola</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mays</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tudor</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Care</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Holland-Bouley</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Everolimus for subependymal giant cell astrocytoma: 5-year final analysis</article-title>
<source/>Ann Neurol
          <volume>78</volume>
<fpage>929</fpage>
<lpage>938</lpage>
<year>2015</year>
<pub-id pub-id-type="pmid">26381530</pub-id>
</element-citation>
</ref>
<ref id="b48-jkns-2019-0027">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Belousova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sparagana</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bebin</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Frost</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kuperman</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study</article-title>
<source/>Lancet Oncol
          <volume>15</volume>
<fpage>1513</fpage>
<lpage>1520</lpage>
<year>2014</year>
<pub-id pub-id-type="pmid">25456370</pub-id>
</element-citation>
</ref>
<ref id="b49-jkns-2019-0027">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>French</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Yapici</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Polster</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nabbout</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study</article-title>
<source/>Lancet
          <volume>388</volume>
<fpage>2153</fpage>
<lpage>2163</lpage>
<year>2016</year>
<pub-id pub-id-type="pmid">27613521</pub-id>
</element-citation>
</ref>
<ref id="b50-jkns-2019-0027">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gingras</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>O’Leary</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Sonenberg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hay</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>4E-BP1, a repressor of mRNA translation, is phosphorylated by the Akt(PKB) signaling pathway</article-title>
<source/>Genes Dev
          <volume>12</volume>
<fpage>502</fpage>
<lpage>513</lpage>
<year>1998</year>
<pub-id pub-id-type="pmid">9472019</pub-id>
</element-citation>
</ref>
<ref id="b51-jkns-2019-0027">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gingras</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Gygi</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Raught</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Polakiewicz</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Hoekstra</surname>
<given-names>MF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Regulation of 4E-BP1 phosphorylation : a novel two-step mechanism</article-title>
<source/>Genes Dev
          <volume>13</volume>
<fpage>1422</fpage>
<lpage>1437</lpage>
<year>1999</year>
<pub-id pub-id-type="pmid">10364159</pub-id>
</element-citation>
</ref>
<ref id="b52-jkns-2019-0027">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gingras</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Raught</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sonenberg</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>eIF4 initiation factors : effectors of mRNA recruitment of translation</article-title>
<source/>Annu Rev Biochem
          <volume>68</volume>
<fpage>913</fpage>
<lpage>963</lpage>
<year>1999</year>
<pub-id pub-id-type="pmid">10872469</pub-id>
</element-citation>
</ref>
<ref id="b53-jkns-2019-0027">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lin T</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Miyares</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activating the translational repressor 4E-BP or reducing S6K-GSK3ß activity prevents accelerated axon growth induced by hyperactive mTOR in vivo</article-title>
<source/>Hum Mol Genet
          <volume>24</volume>
<fpage>5746</fpage>
<lpage>5758</lpage>
<year>2015</year>
<pub-id pub-id-type="pmid">26220974</pub-id>
</element-citation>
</ref>
<ref id="b54-jkns-2019-0027">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tenorio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Arias</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Santos-Simarro</surname>
<given-names>F</given-names>
</name>
<name>
<surname>García-Miñaur</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>JC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>mTOR mutations in Smith-Kingsmore syndrome: four additional patients and a review</article-title>
<source/>Clin Genet
          <volume>93</volume>
<fpage>762</fpage>
<lpage>775</lpage>
<year>2018</year>
<pub-id pub-id-type="pmid">28892148</pub-id>
</element-citation>
</ref>
<ref id="b55-jkns-2019-0027">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Orozco</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Saxton</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Condon</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>Krawczyk</surname>
<given-names>PA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SAMTOR is an S-adenosylmethionine sensor for the mTORC1 pathway</article-title>
<source/>Science
          <volume>358</volume>
<fpage>813</fpage>
<lpage>818</lpage>
<year>2017</year>
<pub-id pub-id-type="pmid">29123071</pub-id>
</element-citation>
</ref>
<ref id="b56-jkns-2019-0027">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hadamitzky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Herring</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kirchhof</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bendix</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Haight</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Keyvani</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Repeated systemic treatment with rapamycin affects behavior and amygdala protein expression in rats</article-title>
<source/>Int J Neuropsychopharmacol
          <volume>21</volume>
<fpage>592</fpage>
<lpage>602</lpage>
<year>2018</year>
<pub-id pub-id-type="pmid">29462337</pub-id>
</element-citation>
</ref>
<ref id="b57-jkns-2019-0027">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>LeucyltRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway</article-title>
<source/>Cell
          <volume>149</volume>
<fpage>410</fpage>
<lpage>424</lpage>
<year>2012</year>
<pub-id pub-id-type="pmid">22424946</pub-id>
</element-citation>
</ref>
<ref id="b58-jkns-2019-0027">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heitman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Movva</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>MN</given-names>
</name>
</person-group>
<article-title>Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast</article-title>
<source/>Science
          <volume>253</volume>
<fpage>905</fpage>
<lpage>909</lpage>
<year>1991</year>
<pub-id pub-id-type="pmid">1715094</pub-id>
</element-citation>
</ref>
<ref id="b59-jkns-2019-0027">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hentges</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The flat-top gene is required for the expansion and regionalization of the telencephalic primordium</article-title>
<source/>Development
          <volume>126</volume>
<fpage>1601</fpage>
<lpage>9</lpage>
<year>1999</year>
<pub-id pub-id-type="pmid">10079223</pub-id>
</element-citation>
</ref>
<ref id="b60-jkns-2019-0027">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiremath</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Rhoads</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Immunological detection of the messenger RNA cap-binding protein</article-title>
<source/>J Biol Chem
          <volume>260</volume>
<fpage>7843</fpage>
<lpage>7849</lpage>
<year>1985</year>
<pub-id pub-id-type="pmid">3891747</pub-id>
</element-citation>
</ref>
<ref id="b61-jkns-2019-0027">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holz</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Ballif</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Gygi</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Blenis</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events</article-title>
<source/>Cell
          <volume>123</volume>
<fpage>569</fpage>
<lpage>580</lpage>
<year>2005</year>
<pub-id pub-id-type="pmid">16286006</pub-id>
</element-citation>
</ref>
<ref id="b62-jkns-2019-0027">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Klann</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression</article-title>
<source/>J Neurosci
          <volume>24</volume>
<fpage>6352</fpage>
<lpage>6361</lpage>
<year>2004</year>
<pub-id pub-id-type="pmid">15254091</pub-id>
</element-citation>
</ref>
<ref id="b63-jkns-2019-0027">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsieh</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Claycomb</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Harrsch</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Naegele</surname>
<given-names>JR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Convulsive seizures from experimental focal cortical dysplasia occur independently of cell misplacement</article-title>
<source/>Nat Commun
          <volume>7</volume>
<fpage>11753</fpage>
<year>2016</year>
<pub-id pub-id-type="pmid">27249187</pub-id>
</element-citation>
</ref>
<ref id="b64-jkns-2019-0027">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huber</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Kayser</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Role for rapid dendritic protein synthesis in hippocampal depression</article-title>
<source/>Science
          <volume>288</volume>
<fpage>1254</fpage>
<lpage>1257</lpage>
<year>2000</year>
<pub-id pub-id-type="pmid">10818003</pub-id>
</element-citation>
</ref>
<ref id="b65-jkns-2019-0027">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dawson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tea</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McAninch</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Piltz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Knockout of the epilepsy gene Depdc5 in mice causes severe embryonic dysmorphology with hyperactivity of mTORC1 signalling</article-title>
<source/>Sci Rep
          <volume>7</volume>
<fpage>12618</fpage>
<year>2017</year>
<pub-id pub-id-type="pmid">28974734</pub-id>
</element-citation>
</ref>
<ref id="b66-jkns-2019-0027">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iffland</surname>
<given-names>PH</given-names>
<suffix>2nd</suffix>
</name>
<name>
<surname>Crino</surname>
<given-names>PB</given-names>
</name>
</person-group>
<article-title>Focal cortical dysplasia: gene mutations, cell signaling, and therapeutic implications</article-title>
<source/>Annu Rev Pathol
          <volume>12</volume>
<fpage>547</fpage>
<lpage>571</lpage>
<year>2017</year>
<pub-id pub-id-type="pmid">28135561</pub-id>
</element-citation>
</ref>
<ref id="b67-jkns-2019-0027">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inoki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>KL</given-names>
</name>
</person-group>
<article-title>Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling</article-title>
<source/>Genes Dev
          <volume>17</volume>
<fpage>1829</fpage>
<lpage>1834</lpage>
<year>2003</year>
<pub-id pub-id-type="pmid">12869586</pub-id>
</element-citation>
</ref>
<ref id="b68-jkns-2019-0027">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jansen</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Mirzaa</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Ishak</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>O’Roak</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Hiatt</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Roden</surname>
<given-names>WH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia</article-title>
<source/>Brain
          <volume>138</volume>
<issue>Pt 6</issue>
<fpage>1613</fpage>
<lpage>1628</lpage>
<year>2015</year>
<pub-id pub-id-type="pmid">25722288</pub-id>
</element-citation>
</ref>
<ref id="b69-jkns-2019-0027">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Genau</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Behrends</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Amino acid-dependent mTORC1 regulation by the lysosomal membrane protein SLC38A9</article-title>
<source/>Mol Cell Biol
          <volume>35</volume>
<fpage>2479</fpage>
<lpage>2494</lpage>
<year>2015</year>
<pub-id pub-id-type="pmid">25963655</pub-id>
</element-citation>
</ref>
<ref id="b70-jkns-2019-0027">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keppler-Noreuil</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>VE</given-names>
</name>
<name>
<surname>Darling</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Martinez-Agosto</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway &amp; therapeutic strategies</article-title>
<source/>Am J Med Genet C Semin Med Genet
          <volume>172</volume>
<fpage>402</fpage>
<lpage>421</lpage>
<year>2016</year>
<pub-id pub-id-type="pmid">27860216</pub-id>
</element-citation>
</ref>
<ref id="b71-jkns-2019-0027">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klawitter</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gottschalk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hainz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Leibfritz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Christians</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Serkova</surname>
<given-names>NJ</given-names>
</name>
</person-group>
<article-title>Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism</article-title>
<source/>Chem Res Toxicol
          <volume>23</volume>
<fpage>608</fpage>
<lpage>619</lpage>
<year>2010</year>
<pub-id pub-id-type="pmid">20148532</pub-id>
</element-citation>
</ref>
<ref id="b72-jkns-2019-0027">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kowalczyk</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Babbs</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sanchez-Pulido</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Szumska</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sharpe</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nprl3 is required for normal development of the cardiovascular system</article-title>
<source/>Mamm Genome
          <volume>23</volume>
<fpage>404</fpage>
<lpage>415</lpage>
<year>2012</year>
<pub-id pub-id-type="pmid">22538705</pub-id>
</element-citation>
</ref>
<ref id="b73-jkns-2019-0027">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Care</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Agricola</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tudor</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mays</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
</person-group>
<article-title>Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma</article-title>
<source/>Neurology
          <volume>80</volume>
<fpage>574</fpage>
<lpage>580</lpage>
<year>2013</year>
<pub-id pub-id-type="pmid">23325902</pub-id>
</element-citation>
</ref>
<ref id="b74-jkns-2019-0027">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Care</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Agricola</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tudor</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mangeshkar</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis</article-title>
<source/>N Engl J Med
          <volume>369</volume>
<fpage>1801</fpage>
<lpage>1811</lpage>
<year>2010</year>
</element-citation>
</ref>
<ref id="b75-jkns-2019-0027">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Wilfong</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Mays</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Talley</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Agricola</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tudor</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term treatment of epilepsy with everolimus in tuberous sclerosis</article-title>
<source/>Neurology
          <volume>87</volume>
<fpage>2408</fpage>
<lpage>2415</lpage>
<year>2016</year>
<pub-id pub-id-type="pmid">27815402</pub-id>
</element-citation>
</ref>
<ref id="b76-jkns-2019-0027">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuegler</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Waldmann</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Baudis</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ilmjärv</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hescheler</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing</article-title>
<source/>ALTEX
          <volume>27</volume>
<fpage>17</fpage>
<lpage>42</lpage>
<year>2010</year>
<pub-id pub-id-type="pmid">20390237</pub-id>
</element-citation>
</ref>
<ref id="b77-jkns-2019-0027">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>MX</given-names>
</name>
<name>
<surname>Swank</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Kunz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways</article-title>
<source/>J Neurosci
          <volume>25</volume>
<fpage>11288</fpage>
<lpage>11299</lpage>
<year>2005</year>
<pub-id pub-id-type="pmid">16339024</pub-id>
</element-citation>
</ref>
<ref id="b78-jkns-2019-0027">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Knoop</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Tharp</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Smeyne</surname>
<given-names>RJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease</article-title>
<source/>Nat Genet
          <volume>29</volume>
<fpage>404</fpage>
<lpage>411</lpage>
<year>2001</year>
<pub-id pub-id-type="pmid">11726927</pub-id>
</element-citation>
</ref>
<ref id="b79-jkns-2019-0027">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Huynh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Silhavy</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dixon-Salazar</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Heiberg</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly</article-title>
<source/>Nat Genet
          <volume>44</volume>
<fpage>941</fpage>
<lpage>945</lpage>
<year>2012</year>
<pub-id pub-id-type="pmid">22729223</pub-id>
</element-citation>
</ref>
<ref id="b80-jkns-2019-0027">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>DW</given-names>
</name>
</person-group>
<article-title>Focal cortical dysplasia and epilepsy surgery</article-title>
<source/>J Epilepsy Res
          <volume>3</volume>
<fpage>43</fpage>
<lpage>47</lpage>
<year>2013</year>
<pub-id pub-id-type="pmid">24649472</pub-id>
</element-citation>
</ref>
<ref id="b81-jkns-2019-0027">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Banasr</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dwyer</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>mTORdependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists</article-title>
<source/>Science
          <volume>329</volume>
<fpage>959</fpage>
<lpage>964</lpage>
<year>2010</year>
<pub-id pub-id-type="pmid">20724638</pub-id>
</element-citation>
</ref>
<ref id="b82-jkns-2019-0027">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lim</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Gopalappa</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Ramakrishna</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>WI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Somatic mutations in TSC1 and TSC2 cause focal cortical dysplasia</article-title>
<source/>Am J Hum Genet
          <volume>100</volume>
<fpage>454</fpage>
<lpage>472</lpage>
<year>2017</year>
<pub-id pub-id-type="pmid">28215400</pub-id>
</element-citation>
</ref>
<ref id="b83-jkns-2019-0027">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lim</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>WI</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>EK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy</article-title>
<source/>Nat Med
          <volume>21</volume>
<fpage>395</fpage>
<lpage>400</lpage>
<year>2015</year>
<pub-id pub-id-type="pmid">25799227</pub-id>
</element-citation>
</ref>
<ref id="b84-jkns-2019-0027">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>TV</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kimura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Malone</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Bordey</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Normalizing translation through 4E-BP prevents mTOR-driven cortical mislamination and ameliorates aberrant neuron integration</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>113</volume>
<fpage>11330</fpage>
<lpage>11335</lpage>
<year>2016</year>
<pub-id pub-id-type="pmid">27647922</pub-id>
</element-citation>
</ref>
<ref id="b85-jkns-2019-0027">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipton</surname>
<given-names>JO</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The neurology of mTOR</article-title>
<source/>Neuron
          <volume>84</volume>
<fpage>275</fpage>
<lpage>291</lpage>
<year>2014</year>
<pub-id pub-id-type="pmid">25374355</pub-id>
</element-citation>
</ref>
<ref id="b86-jkns-2019-0027">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ljungberg</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Bhattacharjee</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Yoshor</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Swann</surname>
<given-names>JW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia</article-title>
<source/>Ann Neurol
          <volume>60</volume>
<fpage>420</fpage>
<lpage>429</lpage>
<year>2006</year>
<pub-id pub-id-type="pmid">16912980</pub-id>
</element-citation>
</ref>
<ref id="b87-jkns-2019-0027">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ljungberg</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Sunnen</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Lugo</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>D’Arcangelo</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia</article-title>
<source/>Dis Model Mech
          <volume>2</volume>
<fpage>389</fpage>
<lpage>398</lpage>
<year>2009</year>
<pub-id pub-id-type="pmid">19470613</pub-id>
</element-citation>
</ref>
<ref id="b88-jkns-2019-0027">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ortiz-Vega</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yonezawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Avruch</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Rheb binds and regulates the mTOR kinase</article-title>
<source/>Curr Biol
          <volume>15</volume>
<fpage>702</fpage>
<lpage>713</lpage>
<year>2005</year>
<pub-id pub-id-type="pmid">15854902</pub-id>
</element-citation>
</ref>
<ref id="b89-jkns-2019-0027">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luikart</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Schnell</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Washburn</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Bensen</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Tovar</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Westbrook</surname>
<given-names>GL</given-names>
</name>
</person-group>
<article-title>Pten knockdown in vivo increases excitatory drive onto dentate granule cells</article-title>
<source/>J Neurosci
          <volume>31</volume>
<fpage>4345</fpage>
<lpage>4354</lpage>
<year>2011</year>
<pub-id pub-id-type="pmid">21411674</pub-id>
</element-citation>
</ref>
<ref id="b90-jkns-2019-0027">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchese</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Conti</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Valvo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Moro</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Muratori</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tancredi</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autism-epilepsy phenotype with macrocephaly suggests PTEN, but not GLIALCAM, genetic screening</article-title>
<source/>BMC Med Genet
          <volume>15</volume>
<fpage>26</fpage>
<year>2014</year>
<pub-id pub-id-type="pmid">24580998</pub-id>
</element-citation>
</ref>
<ref id="b91-jkns-2019-0027">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Baulac</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Review: mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy</article-title>
<source/>Neuropathol Appl Neurobiol
          <volume>44</volume>
<fpage>6</fpage>
<lpage>17</lpage>
<year>2018</year>
<pub-id pub-id-type="pmid">29359340</pub-id>
</element-citation>
</ref>
<ref id="b92-jkns-2019-0027">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ishida</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schramm</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weckhuysen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Muraca</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lecas</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Depdc5 knockout rat: a novel model of mTORopathy</article-title>
<source/>Neurobiol Dis
          <volume>89</volume>
<fpage>180</fpage>
<lpage>189</lpage>
<year>2016</year>
<pub-id pub-id-type="pmid">26873552</pub-id>
</element-citation>
</ref>
<ref id="b93-jkns-2019-0027">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martel</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Klicius</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Galet</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Inhibition of the immune response by rapamycin, a new antifungal antibiotic</article-title>
<source/>Can J Physiol Pharmacol
          <volume>55</volume>
<fpage>48</fpage>
<lpage>51</lpage>
<year>1977</year>
<pub-id pub-id-type="pmid">843990</pub-id>
</element-citation>
</ref>
<ref id="b94-jkns-2019-0027">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Lizana</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fauser</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brandt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schuler</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wiegand</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Doostkam</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term seizure outcome in pediatric patients with focal cortical dysplasia undergoing tailored and standard surgical resections</article-title>
<source/>Seizure
          <volume>62</volume>
<fpage>66</fpage>
<lpage>73</lpage>
<year>2018</year>
<pub-id pub-id-type="pmid">30296740</pub-id>
</element-citation>
</ref>
<ref id="b95-jkns-2019-0027">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mc Cormack</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sharpe</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gregersen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>I</given-names>
</name>
<name>
<surname>George</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>12q14 microdeletions: additional case series with confirmation of a macrocephaly region</article-title>
<source/>Case Rep Genet
          <volume>2015</volume>
<fpage>192071</fpage>
<year>2015</year>
<pub-id pub-id-type="pmid">26266063</pub-id>
</element-citation>
</ref>
<ref id="b96-jkns-2019-0027">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meikle</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Talos</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Onda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pollizzi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rotenberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival</article-title>
<source/>J Neurosci
          <volume>27</volume>
<fpage>5546</fpage>
<lpage>5558</lpage>
<year>2007</year>
<pub-id pub-id-type="pmid">17522300</pub-id>
</element-citation>
</ref>
<ref id="b97-jkns-2019-0027">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mester</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>When overgrowth bumps into cancer: the PTEN-opathies</article-title>
<source/>Am J Med Genet C Semin Med Genet
          <volume>163C</volume>
<fpage>114</fpage>
<lpage>121</lpage>
<year>2013</year>
<pub-id pub-id-type="pmid">23613428</pub-id>
</element-citation>
</ref>
<ref id="b98-jkns-2019-0027">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millichap</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Cowden syndrome with cortical malformation and epilepsy</article-title>
<source/>Pediatr Neurol Briefs
          <volume>34</volume>
<fpage>7</fpage>
<year>2013</year>
</element-citation>
</ref>
<ref id="b99-jkns-2019-0027">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirzaa</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Conway</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Gripp</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Lerman-Sagie</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>deVries</surname>
<given-names>LS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Megalencephaly-capillary malformation (MCAP) and megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndromes: two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis</article-title>
<source/>Am J Med Genet A
          <volume>158A</volume>
<fpage>269</fpage>
<lpage>291</lpage>
<year>2012</year>
<pub-id pub-id-type="pmid">22228622</pub-id>
</element-citation>
</ref>
<ref id="b100-jkns-2019-0027">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyata</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chiang</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Vinters</surname>
<given-names>HV</given-names>
</name>
</person-group>
<article-title>Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis</article-title>
<source/>Ann Neurol
          <volume>56</volume>
<fpage>510</fpage>
<lpage>9</lpage>
<year>2004</year>
<pub-id pub-id-type="pmid">15455398</pub-id>
</element-citation>
</ref>
<ref id="b101-jkns-2019-0027">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moosa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Böhrer-Rabel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Altmüller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beleggia</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nürnberg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Smith-Kingsmore syndrome: a third family with the MTOR mutation c.5395G&gt;A p.(Glu1799Lys) and evidence for paternal gonadal mosaicism</article-title>
<source/>Am J Med Genet A
          <volume>173</volume>
<fpage>264</fpage>
<lpage>267</lpage>
<year>2017</year>
<pub-id pub-id-type="pmid">27753196</pub-id>
</element-citation>
</ref>
<ref id="b102-jkns-2019-0027">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mroske</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rasmussen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shinde</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Huether</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Powis</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>HM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Germline activating MTOR mutation arising through gonadal mosaicism in two brothers with megalencephaly and neurodevelopmental abnormalities</article-title>
<source/>BMC Med Genet
          <volume>16</volume>
<fpage>102</fpage>
<year>2015</year>
<pub-id pub-id-type="pmid">26542245</pub-id>
</element-citation>
</ref>
<ref id="b103-jkns-2019-0027">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muncy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>IJ</given-names>
</name>
<name>
<surname>Koenig</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Rapamycin reduces seizure frequency in tuberous sclerosis complex</article-title>
<source/>J Child Neurol
          <volume>24</volume>
<fpage>477</fpage>
<year>2009</year>
<pub-id pub-id-type="pmid">19151365</pub-id>
</element-citation>
</ref>
<ref id="b104-jkns-2019-0027">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nellist</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schot</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hoogeveen-Westerveld</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Neuteboom</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>van der Louw</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Lequin</surname>
<given-names>MH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Germline activating AKT3 mutation associated with megalencephaly, polymicrogyria, epilepsy and hypoglycemia</article-title>
<source/>Mol Genet Metab
          <volume>114</volume>
<fpage>467</fpage>
<lpage>473</lpage>
<year>2015</year>
<pub-id pub-id-type="pmid">25523067</pub-id>
</element-citation>
</ref>
<ref id="b105-jkns-2019-0027">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Jacinto</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>mTOR complex 2 signaling and functions</article-title>
<source/>Cell Cycle
          <volume>10</volume>
<fpage>2305</fpage>
<lpage>2316</lpage>
<year>2011</year>
<pub-id pub-id-type="pmid">21670596</pub-id>
</element-citation>
</ref>
<ref id="b106-jkns-2019-0027">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orloff</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Mester</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Germline PIK3CA and AKT1 mutations in cowden and cowden-like syndromes</article-title>
<source/>Am J Hum Genet
          <volume>92</volume>
<fpage>76</fpage>
<lpage>80</lpage>
<year>2013</year>
<pub-id pub-id-type="pmid">23246288</pub-id>
</element-citation>
</ref>
<ref id="b107-jkns-2019-0027">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orlova</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Heuer</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baybis</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>STRADa deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice</article-title>
<source/>J Clin Invest
          <volume>120</volume>
<fpage>1591</fpage>
<lpage>1602</lpage>
<year>2010</year>
<pub-id pub-id-type="pmid">20424326</pub-id>
</element-citation>
</ref>
<ref id="b108-jkns-2019-0027">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pajusalu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Reimand</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Õunap</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Novel homozygous mutation in KPTN gene causing a familial intellectual disability-macrocephaly syndrome</article-title>
<source/>Am J Med Genet A
          <volume>167A</volume>
<fpage>1913</fpage>
<lpage>1915</lpage>
<year>2015</year>
<pub-id pub-id-type="pmid">25847626</pub-id>
</element-citation>
</ref>
<ref id="b109-jkns-2019-0027">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pallet</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Legendre</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Adverse events associated with mTOR inhibitors</article-title>
<source/>Expert Opin Drug Saf
          <volume>12</volume>
<fpage>177</fpage>
<lpage>186</lpage>
<year>2013</year>
<pub-id pub-id-type="pmid">23252795</pub-id>
</element-citation>
</ref>
<ref id="b110-jkns-2019-0027">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Ramakrishina</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain somatic mutations in MTOR disrupt neuronal ciliogenesis, leading to focal cortical dyslamination</article-title>
<source/>Neuron
          <volume>99</volume>
<fpage>83</fpage>
<lpage>97</lpage>
<comment>e7</comment>
<year>2018</year>
<pub-id pub-id-type="pmid">29937275</pub-id>
</element-citation>
</ref>
<ref id="b111-jkns-2019-0027">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parker</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Orlova</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Birnbaum</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Krymskaya</surname>
<given-names>VP</given-names>
</name>
<name>
<surname>Goncharov</surname>
<given-names>DA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder</article-title>
<source/>Sci Transl Med
          <volume>5</volume>
<fpage>182ra53</fpage>
<year>2013</year>
</element-citation>
</ref>
<ref id="b112-jkns-2019-0027">
<label>112</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peters</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Taquet</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Prohl</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Scherrer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>van Eeghen</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Prabhu</surname>
<given-names>SP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions</article-title>
<source/>Future Neurol
          <volume>8</volume>
<fpage>583</fpage>
<lpage>597</lpage>
<year>2013</year>
<pub-id pub-id-type="pmid">24489482</pub-id>
</element-citation>
</ref>
<ref id="b113-jkns-2019-0027">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pilarski</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Cowden syndrome: a critical review of the clinical literature</article-title>
<source/>J Genet Couns
          <volume>18</volume>
<fpage>13</fpage>
<lpage>27</lpage>
<year>2009</year>
<pub-id pub-id-type="pmid">18972196</pub-id>
</element-citation>
</ref>
<ref id="b114-jkns-2019-0027">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitkänen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lukasiuk</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Mechanisms of epileptogenesis and potential treatment targets</article-title>
<source/>Lancet Neurol
          <volume>10</volume>
<fpage>173</fpage>
<lpage>186</lpage>
<year>2011</year>
<pub-id pub-id-type="pmid">21256455</pub-id>
</element-citation>
</ref>
<ref id="b115-jkns-2019-0027">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poduri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Evrony</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Elhosary</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Beroukhim</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lehtinen</surname>
<given-names>MK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Somatic activation of AKT3 causes hemispheric developmental brain malformations</article-title>
<source/>Neuron
          <volume>74</volume>
<fpage>41</fpage>
<lpage>48</lpage>
<year>2012</year>
<pub-id pub-id-type="pmid">22500628</pub-id>
</element-citation>
</ref>
<ref id="b116-jkns-2019-0027">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porstmann</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Griffiths</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cully</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leevers</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth</article-title>
<source/>Cell Metab
          <volume>8</volume>
<fpage>224</fpage>
<lpage>236</lpage>
<year>2008</year>
<pub-id pub-id-type="pmid">18762023</pub-id>
</element-citation>
</ref>
<ref id="b117-jkns-2019-0027">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raab-Graham</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Haddick</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Jan</surname>
<given-names>YN</given-names>
</name>
<name>
<surname>Jan</surname>
<given-names>LY</given-names>
</name>
</person-group>
<article-title>Activity- and mTORdependent suppression of Kv1.1 channel mRNA translation in dendrites</article-title>
<source/>Science
          <volume>314</volume>
<fpage>144</fpage>
<lpage>148</lpage>
<year>2006</year>
<pub-id pub-id-type="pmid">17023663</pub-id>
</element-citation>
</ref>
<ref id="b118-jkns-2019-0027">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rabanal-Ruiz</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Otten</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Korolchuk</surname>
<given-names>VI</given-names>
</name>
</person-group>
<article-title>mTORC1 as the main gateway to autophagy</article-title>
<source/>Essays Biochem
          <volume>61</volume>
<fpage>565</fpage>
<lpage>584</lpage>
<year>2017</year>
<pub-id pub-id-type="pmid">29233869</pub-id>
</element-citation>
</ref>
<ref id="b119-jkns-2019-0027">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rennebeck</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kleymenova</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yeung</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Artzt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>CL</given-names>
</name>
</person-group>
<article-title>Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>95</volume>
<fpage>15629</fpage>
<lpage>15634</lpage>
<year>1998</year>
<pub-id pub-id-type="pmid">9861021</pub-id>
</element-citation>
</ref>
<ref id="b120-jkns-2019-0027">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ribierre</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Deleuze</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bacq</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Baldassari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marsan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chipaux</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Second-hit mosaic mutation in mTORC1 repressor DEPDC5 causes focal cortical dysplasia-associated epilepsy</article-title>
<source/>J Clin Investig
          <volume>128</volume>
<fpage>2452</fpage>
<lpage>2458</lpage>
<year>2018</year>
<pub-id pub-id-type="pmid">29708508</pub-id>
</element-citation>
</ref>
<ref id="b121-jkns-2019-0027">
<label>121</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ricos</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Hodgson</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Pippucci</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Saidin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ong</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Heron</surname>
<given-names>SE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy</article-title>
<source/>Ann Neurol
          <volume>79</volume>
<fpage>120</fpage>
<lpage>131</lpage>
<year>2016</year>
<pub-id pub-id-type="pmid">26505888</pub-id>
</element-citation>
</ref>
<ref id="b122-jkns-2019-0027">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rivière</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Mirzaa</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>O’Roak</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Beddaoui</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alcantara</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Conway</surname>
<given-names>RL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes</article-title>
<source/>Nat Genet
          <volume>44</volume>
<fpage>934</fpage>
<lpage>940</lpage>
<year>2012</year>
<pub-id pub-id-type="pmid">22729224</pub-id>
</element-citation>
</ref>
<ref id="b123-jkns-2019-0027">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Skibo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kalume</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rankin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy</article-title>
<source/>Elife
          <volume>4</volume>
<fpage>e12703</fpage>
<year>2015</year>
<pub-id pub-id-type="pmid">26633882</pub-id>
</element-citation>
</ref>
<ref id="b124-jkns-2019-0027">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabatini</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Twenty-five years of mTOR: uncovering the link from nutrients to growth</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>114</volume>
<fpage>11818</fpage>
<lpage>11825</lpage>
<year>2017</year>
<pub-id pub-id-type="pmid">29078414</pub-id>
</element-citation>
</ref>
<ref id="b125-jkns-2019-0027">
<label>125</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabatini</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Erdjument-Bromage</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lui</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tempst</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs</article-title>
<source/>Cell
          <volume>78</volume>
<fpage>35</fpage>
<lpage>43</lpage>
<year>1994</year>
<pub-id pub-id-type="pmid">7518356</pub-id>
</element-citation>
</ref>
<ref id="b126-jkns-2019-0027">
<label>126</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salinas</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Vega</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Piccirilli</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Chicco</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ciraolo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Christiansen</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of a somatic mutation in the RHEB gene through high depth and ultra-high depth next generation sequencing in a patient with Hemimegalencephaly and drug resistant Epilepsy</article-title>
<source/>Eur J Med Genet
          <year>2018</year>
<comment>[Epub ahead of print]</comment>
</element-citation>
</ref>
<ref id="b127-jkns-2019-0027">
<label>127</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sancak</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Shaul</surname>
<given-names>YD</given-names>
</name>
<name>
<surname>Lindquist</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Thoreen</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Bar-Peled</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The rag GTPases bind raptor and mediate amino acid signaling to mTORC1</article-title>
<source/>Science
          <volume>320</volume>
<fpage>1496</fpage>
<lpage>1501</lpage>
<year>2008</year>
<pub-id pub-id-type="pmid">18497260</pub-id>
</element-citation>
</ref>
<ref id="b128-jkns-2019-0027">
<label>128</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarbassov</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Guertin</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</article-title>
<source/>Science
          <volume>307</volume>
<fpage>1098</fpage>
<lpage>1101</lpage>
<year>2005</year>
<pub-id pub-id-type="pmid">15718470</pub-id>
</element-citation>
</ref>
<ref id="b129-jkns-2019-0027">
<label>129</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saré</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Loutaev</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maita</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lemons</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Negative effects of chronic rapamycin treatment on behavior in a mouse model of fragile X syndrome</article-title>
<source/>Front Mol Neurosci
          <volume>10</volume>
<fpage>452</fpage>
<year>2018</year>
<pub-id pub-id-type="pmid">29375310</pub-id>
</element-citation>
</ref>
<ref id="b130-jkns-2019-0027">
<label>130</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saxton</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>mTOR signaling in growth, metabolism, and disease</article-title>
<source/>Cell
          <volume>168</volume>
<fpage>960</fpage>
<lpage>976</lpage>
<year>2017</year>
<pub-id pub-id-type="pmid">28283069</pub-id>
</element-citation>
</ref>
<ref id="b131-jkns-2019-0027">
<label>131</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scerri</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Riseley</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Gillies</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pope</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Burgess</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mandelstam</surname>
<given-names>SA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5</article-title>
<source/>Ann Clin Transl Neurol
          <volume>2</volume>
<fpage>575</fpage>
<lpage>580</lpage>
<year>2015</year>
<pub-id pub-id-type="pmid">26000329</pub-id>
</element-citation>
</ref>
<ref id="b132-jkns-2019-0027">
<label>132</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schick</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Majores</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Engels</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Spitoni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Elger</surname>
<given-names>CE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of Akt independent of PTEN and CTMP tumor-suppressor gene mutations in epilepsy-associated Taylor-type focal cortical dysplasias</article-title>
<source/>Acta Neuropathol
          <volume>112</volume>
<fpage>715</fpage>
<lpage>725</lpage>
<year>2006</year>
<pub-id pub-id-type="pmid">17013611</pub-id>
</element-citation>
</ref>
<ref id="b133-jkns-2019-0027">
<label>133</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartzkroin</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Cortical malformations and epilepsy</article-title>
<source/>Ment Retard Dev Disabil Res Rev
          <volume>6</volume>
<fpage>268</fpage>
<lpage>280</lpage>
<year>2000</year>
<pub-id pub-id-type="pmid">11107192</pub-id>
</element-citation>
</ref>
<ref id="b134-jkns-2019-0027">
<label>134</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sim</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Scerri</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fanjul-Fernández</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Riseley</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Gillies</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pope</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3</article-title>
<source/>Ann Neurol
          <volume>79</volume>
<fpage>132</fpage>
<lpage>137</lpage>
<year>2016</year>
<pub-id pub-id-type="pmid">26285051</pub-id>
</element-citation>
</ref>
<ref id="b135-jkns-2019-0027">
<label>135</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sonenberg</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hinnebusch</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Regulation of translation initiation in eukaryotes: mechanisms and biological targets</article-title>
<source/>Cell
          <volume>136</volume>
<fpage>731</fpage>
<lpage>745</lpage>
<year>2009</year>
<pub-id pub-id-type="pmid">19239892</pub-id>
</element-citation>
</ref>
<ref id="b136-jkns-2019-0027">
<label>136</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Southwell</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Skotte</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Hayden</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases</article-title>
<source/>Trends Mol Med
          <volume>18</volume>
<fpage>634</fpage>
<lpage>643</lpage>
<year>2012</year>
<pub-id pub-id-type="pmid">23026741</pub-id>
</element-citation>
</ref>
<ref id="b137-jkns-2019-0027">
<label>137</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gudsnuk</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Cotrina</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Rosoklija</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sosunov</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits</article-title>
<source/>Neuron
          <volume>83</volume>
<fpage>1131</fpage>
<lpage>1143</lpage>
<year>2014</year>
<pub-id pub-id-type="pmid">25155956</pub-id>
</element-citation>
</ref>
<ref id="b138-jkns-2019-0027">
<label>138</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tavazoie</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Ridenour</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Kwiatkowski</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>BL</given-names>
</name>
</person-group>
<article-title>Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2</article-title>
<source/>Nat Neurosci
          <volume>8</volume>
<fpage>1727</fpage>
<lpage>1734</lpage>
<year>2005</year>
<pub-id pub-id-type="pmid">16286931</pub-id>
</element-citation>
</ref>
<ref id="b139-jkns-2019-0027">
<label>139</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teutonico</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schena</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Di Paolo</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus</article-title>
<source/>J Am Soc Nephrol
          <volume>16</volume>
<fpage>3128</fpage>
<lpage>3135</lpage>
<year>2005</year>
<pub-id pub-id-type="pmid">16107580</pub-id>
</element-citation>
</ref>
<ref id="b140-jkns-2019-0027">
<label>140</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tokuda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mahaffey</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Monks</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Faulkner</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Birnbaum</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Danzer</surname>
<given-names>SC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel Akt3 mutation associated with enhanced kinase activity and seizure susceptibility in mice</article-title>
<source/>Hum Mol Genet
          <volume>20</volume>
<fpage>988</fpage>
<lpage>999</lpage>
<year>2011</year>
<pub-id pub-id-type="pmid">21159799</pub-id>
</element-citation>
</ref>
<ref id="b141-jkns-2019-0027">
<label>141</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uhlmann</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baldwin</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Bajenaru</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Onda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kwiatkowski</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures</article-title>
<source/>Ann Neurol
          <volume>52</volume>
<fpage>285</fpage>
<lpage>296</lpage>
<year>2002</year>
<pub-id pub-id-type="pmid">12205640</pub-id>
</element-citation>
</ref>
<ref id="b142-jkns-2019-0027">
<label>142</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Slegtenhorst</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Hoogt</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hermans</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nellist</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Janssen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Verhoef</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34</article-title>
<source/>Science
          <volume>277</volume>
<fpage>805</fpage>
<lpage>808</lpage>
<year>1997</year>
<pub-id pub-id-type="pmid">9242607</pub-id>
</element-citation>
</ref>
<ref id="b143-jkns-2019-0027">
<label>143</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venkatesan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Angle</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Millichap</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Early-life epileptic encephalopathy secondary to SZT2 pathogenic recessive variants</article-title>
<source/>Epileptic Disord
          <volume>18</volume>
<fpage>195</fpage>
<lpage>200</lpage>
<year>2016</year>
<pub-id pub-id-type="pmid">27248490</pub-id>
</element-citation>
</ref>
<ref id="b144-jkns-2019-0027">
<label>144</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vézina</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kudelski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sehgal</surname>
<given-names>SN</given-names>
</name>
</person-group>
<article-title>Rapamycin (AY-22,989), a new antifungal antibiotic I. Taxonomy of the producing Streptomycete and isolation of the active principle</article-title>
<source/>J Antibiot (Tokyo)
          <volume>28</volume>
<fpage>721</fpage>
<lpage>726</lpage>
<year>1975</year>
<pub-id pub-id-type="pmid">1102508</pub-id>
</element-citation>
</ref>
<ref id="b145-jkns-2019-0027">
<label>145</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>von der Brelie</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Waltereit</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kirschstein</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Impaired synaptic plasticity in a rat model of tuberous sclerosis</article-title>
<source/>Eur J Neurosci
          <volume>23</volume>
<fpage>686</fpage>
<lpage>692</lpage>
<year>2006</year>
<pub-id pub-id-type="pmid">16487150</pub-id>
</element-citation>
</ref>
<ref id="b146-jkns-2019-0027">
<label>146</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wahl</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>McLane</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Bercury</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Macklin</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>TL</given-names>
</name>
</person-group>
<article-title>Mammalian target of rapamycin promotes oligodendrocyte differentiation, initiation and extent of CNS myelination</article-title>
<source/>J Neurosci
          <volume>34</volume>
<fpage>4453</fpage>
<lpage>4465</lpage>
<year>2014</year>
<pub-id pub-id-type="pmid">24671992</pub-id>
</element-citation>
</ref>
<ref id="b147-jkns-2019-0027">
<label>147</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Way</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Mckenna J</surname>
<given-names>3rd</given-names>
</name>
<name>
<surname>Mietzsch</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Reith</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Gambello</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse</article-title>
<source/>Hum Mol Genet
          <volume>18</volume>
<fpage>1252</fpage>
<lpage>1265</lpage>
<year>2009</year>
<pub-id pub-id-type="pmid">19150975</pub-id>
</element-citation>
</ref>
<ref id="b148-jkns-2019-0027">
<label>148</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weston</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Swann</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission</article-title>
<source/>J Neurosci
          <volume>32</volume>
<fpage>11441</fpage>
<lpage>11452</lpage>
<year>2012</year>
<pub-id pub-id-type="pmid">22895726</pub-id>
</element-citation>
</ref>
<ref id="b149-jkns-2019-0027">
<label>149</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiemer-Kruel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Woerle</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Strobl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bast</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report</article-title>
<source/>Neuropediatrics
          <volume>45</volume>
<fpage>129</fpage>
<lpage>131</lpage>
<year>2014</year>
<pub-id pub-id-type="pmid">24293099</pub-id>
</element-citation>
</ref>
<ref id="b150-jkns-2019-0027">
<label>150</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolfson</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Chantranupong</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wyant</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Orozco</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1</article-title>
<source/>Nature
          <volume>543</volume>
<fpage>438</fpage>
<lpage>442</lpage>
<year>2017</year>
<pub-id pub-id-type="pmid">28199306</pub-id>
</element-citation>
</ref>
<ref id="b151-jkns-2019-0027">
<label>151</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wyant</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Abu-Remaileh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Frenkel</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Laqtom</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Dharamdasani</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>CA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nufip1 is a ribosome receptor for starvation-induced ribophagy</article-title>
<source/>Science
          <volume>360</volume>
<fpage>751</fpage>
<lpage>758</lpage>
<year>2018</year>
<pub-id pub-id-type="pmid">29700228</pub-id>
</element-citation>
</ref>
<ref id="b152-jkns-2019-0027">
<label>152</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Oviedo</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>Trotman</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Zador</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>PTEN regulation of local and long-range connections in mouse auditory cortex</article-title>
<source/>J Neurosci
          <volume>32</volume>
<fpage>1643</fpage>
<lpage>1652</lpage>
<year>2012</year>
<pub-id pub-id-type="pmid">22302806</pub-id>
</element-citation>
</ref>
<ref id="b153-jkns-2019-0027">
<label>153</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Uliel-Sibony</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dunham</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sarnat</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Flores-Sarnat</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brunga</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>mTOR inhibitors as a new therapeutic strategy in treatment resistant epilepsy in hemimegalencephaly: a case report</article-title>
<source/>J Child Neurol
          <volume>34</volume>
<fpage>132</fpage>
<lpage>138</lpage>
<year>2019</year>
<pub-id pub-id-type="pmid">30514132</pub-id>
</element-citation>
</ref>
<ref id="b154-jkns-2019-0027">
<label>154</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeung</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Katsetos</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Klein-szanto</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis</article-title>
<source/>Am J Pathol
          <volume>151</volume>
<fpage>1477</fpage>
<lpage>1486</lpage>
<year>1997</year>
<pub-id pub-id-type="pmid">9358774</pub-id>
</element-citation>
</ref>
<ref id="b155-jkns-2019-0027">
<label>155</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeung</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Testa</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Knudson</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>91</volume>
<fpage>11413</fpage>
<lpage>11416</lpage>
<year>1994</year>
<pub-id pub-id-type="pmid">7972075</pub-id>
</element-citation>
</ref>
<ref id="b156-jkns-2019-0027">
<label>156</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Zivraj</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Holt</surname>
<given-names>CE</given-names>
</name>
</person-group>
<article-title>Local translation and mRNA trafficking in axon pathfinding</article-title>
<source/>Results Probl Cell Differ
          <volume>48</volume>
<fpage>269</fpage>
<lpage>288</lpage>
<year>2009</year>
<pub-id pub-id-type="pmid">19343311</pub-id>
</element-citation>
</ref>
<ref id="b157-jkns-2019-0027">
<label>157</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Rensing</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Gambello</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex</article-title>
<source/>Hum Mol Genet
          <volume>20</volume>
<fpage>445</fpage>
<lpage>454</lpage>
<year>2011</year>
<pub-id pub-id-type="pmid">21062901</pub-id>
</element-citation>
</ref>
<ref id="b158-jkns-2019-0027">
<label>158</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex</article-title>
<source/>Ann Neurol
          <volume>63</volume>
<fpage>444</fpage>
<lpage>453</lpage>
<year>2008</year>
<pub-id pub-id-type="pmid">18389497</pub-id>
</element-citation>
</ref>
<ref id="b159-jkns-2019-0027">
<label>159</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoncu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Efeyan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>MTOR: from growth signal integration to cancer, diabetes and ageing</article-title>
<source/>Nat Rev Mol Cell Biol
          <volume>12</volume>
<fpage>21</fpage>
<lpage>35</lpage>
<year>2011</year>
<pub-id pub-id-type="pmid">21157483</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-jkns-2019-0027" orientation="portrait" position="float">
<label>Fig. 1.</label>
<caption>
<p>mTORC1 and mTORC2. A : The components of mTORC1 and respective binding site on mTOR. B : The components of mTORC2 and respective binding site on mTOR. PRAS40 : proline-rich Akt substrate of 40 kDa, Raptor : regulatory protein associated with mTOR, FKBP12 : FK506 binding protein 12, Deptor : DEP domain-containing mTORinteracting protein, mLST8 : mammalian lethal with Sec13 protein 8, mTOR : mechanistic target of rapamycin, mTORC1 : mTOR complex 1, mSin1 : mammalian stress-activated protein kinase-interacting protein, Rictor : rapamycin-insensitive companion of mammalian target of rapamycin, mTORC2 : mTOR complex 2.</p>
</caption>
<graphic xlink:href="jkns-2019-0027f1"></graphic>
</fig>
<fig id="f2-jkns-2019-0027" orientation="portrait" position="float">
<label>Fig. 2.</label>
<caption>
<p>Upstream and downstream of mTORC1 and mTORC2. The signaling network of mTORC1 and mTORC2. Positive regulators of mTORC1 signaling are shown in blue to green. Negative regulators of mTORC1 signaling are shown in red to yellow.</p>
</caption>
<graphic xlink:href="jkns-2019-0027f2"></graphic>
</fig>
<table-wrap id="t1-jkns-2019-0027" orientation="portrait" position="float">
<label>Table 1.</label>
<caption>
<p>Mutations in the mTOR pathway in the neurodevelopmental disorders with epilepsy</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="middle">Gene</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Mutation type</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Effect of the mutation on the mTOR pathway</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PIK3CA</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Germline</td>
<td align="center" colspan="1" rowspan="1" valign="top">Activating</td>
<td align="left" colspan="1" rowspan="1" valign="top">CS, PROS</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Somatic</td>
<td align="center" colspan="1" rowspan="1" valign="top">Activating</td>
<td align="left" colspan="1" rowspan="1" valign="top">PROS, MEG, HME, MCAP, MPPH, FCD</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>PTEN</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Germline</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">CS, BRRS, LDD, Proteus syndrome, Proteus-like syndrome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>AKT3</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Germline</td>
<td align="center" colspan="1" rowspan="1" valign="top">Activating</td>
<td align="left" colspan="1" rowspan="1" valign="top">MEG, HME, MEG with polymicrogyria, MEG with PNH</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Somatic</td>
<td align="center" colspan="1" rowspan="1" valign="top">Activating</td>
<td align="left" colspan="1" rowspan="1" valign="top">HME, FCD</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>TSC1/2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Germline</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">TSC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Inherited – autosomal dominant</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">TSC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Somatic</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">FCD</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>TBC1D7</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inherited – autosomal recessive</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">MEG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>RHEB</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Somatic</td>
<td align="center" colspan="1" rowspan="1" valign="top">Activating</td>
<td align="left" colspan="1" rowspan="1" valign="top">HME</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>STRADA</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inherited – autosomal recessive</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">PMSE</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>MTOR</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Germline</td>
<td align="center" colspan="1" rowspan="1" valign="top">Activating</td>
<td align="left" colspan="1" rowspan="1" valign="top">SKS</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Somatic</td>
<td align="center" colspan="1" rowspan="1" valign="top">Activating</td>
<td align="left" colspan="1" rowspan="1" valign="top">SKS, FCD, HME</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>DEPDC5</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inherited – autosomal dominant</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">FFEVF, ADNFLE, FMTLE</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Germline</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">MCD, epileptic spasm, FCD</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Somatic</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">FCD, pachygyria, MCD</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>NPRL2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Germline</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">TLE, MCD</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>NPRL3</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Germline</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">TLE, MCD, FCD</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>KPTN</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inherited – autosomal recessive</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">Familial intellectual disability-macrocephaly syndrome, Macrocephaly</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SZT2</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inherited – autosomal recessive</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">Infantile encephalopathy with epilepsy</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>C12ORF66</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Germline</td>
<td align="center" colspan="1" rowspan="1" valign="top">Inactivating</td>
<td align="left" colspan="1" rowspan="1" valign="top">Macrocephaly</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>mTOR : mechanistic target of rapamycin, CS : cowden syndrome, PROS : PIK3CA-related overgrowth spectrum, MEG : megalencephaly, HME : hemimegalencephaly, MCAP : megalencephaly-capillary malformation, MPPH : megalencephaly-polydactylyl-polymicrogyria-hydrocephalus, FCD : focal cortical dysplasia, PTEN : phosphatase and tensin homolog, BRRS : Bannayan-Riley-Ruvalcaba syndrome, LDD : Lhermitte-Duclos disease, PNH : periventricular nodular heterotopia, TSC : tuberous sclerosis, RHEB : Ras homolog enriched in brain, STRADA : STE20-related kinase adaptor α, PMSE : polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome, MTOR : mechanistic target of rapamycin, SKS : Smith-Kingsmore syndrome, FFEVF : familial focal epilepsy with variable foci, ADNFLE : autosomal dominant nocturnal epilepsy, FMTLE : familial mesial temporal lobe epilepsy, TLE : temporal lobe epilepsy</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="t2-jkns-2019-0027" orientation="portrait" position="float">
<label>Table 2.</label>
<caption>
<p>Epilepsy animal models with genetic mTOR pathway hyperactivation</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="middle">Gene</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Role and function</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Genotype</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PI3K</td>
<td align="left" colspan="1" rowspan="1" valign="top">PI3K is a critical signaling pathway which integrates insulin signaling to the growth and survival</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hyperactive <italic>Pik3ca</italic> Nestin KI</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b22-jkns-2019-0027">22</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PTEN</td>
<td align="left" colspan="1" rowspan="1" valign="top">PTEN is a phosphatase and a negative regulator of the PI3K-PTEN-AKT-TSC pathway</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>Pten</italic> KO</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b1-jkns-2019-0027">1</xref>,<xref ref-type="bibr" rid="b14-jkns-2019-0027">14</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>Pten</italic> GFAP KO</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b13-jkns-2019-0027">13</xref>,<xref ref-type="bibr" rid="b17-jkns-2019-0027">17</xref>,<xref ref-type="bibr" rid="b23-jkns-2019-0027">23</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>Pten</italic> NSE KO</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b33-jkns-2019-0027">33</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Inducible <italic>Pten</italic> KO</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b145-jkns-2019-0027">145</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">AKT</td>
<td align="left" colspan="1" rowspan="1" valign="top">AKT is a positive regulator of the mTORCl via inhibition of TSC and the mTORC2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Akt3 KI</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b25-jkns-2019-0027">25</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Hyperactive <italic>Akt3</italic> KI via <italic>in utero</italic> electroporation at the SVZ</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b2-jkns-2019-0027">2</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TSC1/2</td>
<td align="left" colspan="1" rowspan="1" valign="top">TSC1/2 is a negative regulator of the mTORCl via inhibiting the action of RHEB</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>Tsc1</italic> GFAP KO</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b26-jkns-2019-0027">26</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>Tsc1</italic> SynI KO</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b37-jkns-2019-0027">37</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>Tsc1</italic> Nestin KO</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b8-jkns-2019-0027">8</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>Tsc1</italic> Emxl KO</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b4-jkns-2019-0027">4</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>Tsc1</italic> KO via <italic>in utero</italic> electroporation at the SVZ</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b15-jkns-2019-0027">15</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>Tsc2</italic> GFAP KO</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b27-jkns-2019-0027">27</xref>,<xref ref-type="bibr" rid="b44-jkns-2019-0027">44</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>Tsc2</italic> KO via <italic>in utero</italic> electroporation at the SVZ</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b15-jkns-2019-0027">15</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">mTOR</td>
<td align="left" colspan="1" rowspan="1" valign="top">mTOR is a serine/threonine kinase regulating various downstream targets which coordinate metabolism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hyperactive <italic>MTOR</italic> KI via <italic>in utero</italic> electroporation at the SVZ</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b16-jkns-2019-0027">16</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">RHEB</td>
<td align="left" colspan="1" rowspan="1" valign="top">RHEB activate the mTORC1 on the lysosomal membrane</td>
<td align="left" colspan="1" rowspan="1" valign="top">Constitutively active <italic>Rheb</italic> KI via <italic>in utero</italic> electroporation at the SVZ</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b9-jkns-2019-0027">9</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">DEPDC5</td>
<td align="left" colspan="1" rowspan="1" valign="top">DEPDC5 comprise the amino acid-sensing pathway and is a negative regulator of the mTORCl</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>Depdc5</italic> KO via <italic>in utero</italic> electroporation at the SVZ in <italic>Depec5</italic> +/- mouse</td>
<td align="center" colspan="1" rowspan="1" valign="top">[<xref ref-type="bibr" rid="b21-jkns-2019-0027">21</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>mTOR : mechanistic target of rapamycin, PI3K : phosphatidylinositol-3-kinase, KI : knock-in, PTEN : phosphatase and tensin homologon chromosome 10, GFAP : glial fibrillary acidic protein, KO : knock-out, NSE : neuron specific enonlase, SVZ : subventricular zone, TSC : tuberous sclerosis, SynI : synapsin I, RHEB : Ras homologue enriched in brain</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="t3-jkns-2019-0027" orientation="portrait" position="float">
<label>Table 3.</label>
<caption>
<p>Clinical studies with the mTOR inhibitors for the anti-epileptic effects</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="middle">Type of study</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Disease</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Drug and dose</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Number and age of patient(s)</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Duration of treatment</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Anti-epileptic effect</th>
<th align="center" colspan="1" rowspan="1" valign="middle">Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Prospective, open-label, phase I/II clinical trial</td>
<td align="left" colspan="1" rowspan="2" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Everolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">16 patients; 3 year-old or older</td>
<td align="left" colspan="1" rowspan="2" valign="top">Median duration : 21.5 months (range, 4.7–34.4)</td>
<td align="left" colspan="1" rowspan="2" valign="top">Reduction in seizure frequency in 9/16 patients</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b11-jkns-2019-0027">11</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">4.7–5.6 mg/m<sup>2</sup>/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Case report</td>
<td align="left" colspan="1" rowspan="2" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Everolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">1 patient; 10-year-old man</td>
<td align="left" colspan="1" rowspan="2" valign="top">12 months</td>
<td align="left" colspan="1" rowspan="2" valign="top">Cessation of seizure</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b20-jkns-2019-0027">20</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">4.5 mg/m<sup>2</sup>/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Prospective, multicenter, openlabel, phase I/II clinical trial</td>
<td align="left" colspan="1" rowspan="2" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Everolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">20 patients; median age : 8 years (age range, 2–21)</td>
<td align="left" colspan="1" rowspan="2" valign="top">12 weeks</td>
<td align="left" colspan="1" rowspan="2" valign="top">Reduction in seizure frequency in 17/20 patients, 4 ofthese patients were seizure-free at 12 weeks</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b24-jkns-2019-0027">24</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5 mg/m<sup>2</sup>/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Prospective, double-blind, parallel-group, placebo-controlled, multicenter phase III</td>
<td align="left" colspan="1" rowspan="2" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Everolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">8 patients, children under the age of 3</td>
<td align="left" colspan="1" rowspan="2" valign="top">35 months (range, 33–38)</td>
<td align="left" colspan="1" rowspan="2" valign="top">Cessation of seizures in 1 patient, significant (at least a 50%) reduction in the number of seizures in 2 patients</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b10-jkns-2019-0027">10</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">4.5 mg/m<sup>2</sup>/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Case study series</td>
<td align="left" colspan="1" rowspan="2" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Everolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">6 patients; median age : 5 years (age range, 2–12)</td>
<td align="left" colspan="1" rowspan="2" valign="top">36 weeks</td>
<td align="left" colspan="1" rowspan="2" valign="top">Reduction in seizure frequency in 4/6 patients</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b29-jkns-2019-0027">29</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5–7 mg/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Open-label, single center case series</td>
<td align="left" colspan="1" rowspan="2" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Everolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">1 patients; 14-year-old female</td>
<td align="left" colspan="1" rowspan="2" valign="top">18 months</td>
<td align="left" colspan="1" rowspan="2" valign="top">25-50% seizure reduction</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b3-jkns-2019-0027">3</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5 mg/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Case study</td>
<td align="left" colspan="1" rowspan="2" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Everolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">1 patient; 13.5-year-old female</td>
<td align="left" colspan="1" rowspan="2" valign="top">12 days</td>
<td align="left" colspan="1" rowspan="2" valign="top">Seizure aggravation</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b30-jkns-2019-0027">30</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5 mg/m<sup>2</sup>/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Case study</td>
<td align="left" colspan="1" rowspan="2" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Everolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">1 patient; 13-year-old female</td>
<td align="left" colspan="1" rowspan="2" valign="top">1.5 year</td>
<td align="left" colspan="1" rowspan="2" valign="top">Reduction in seizure frequency</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b28-jkns-2019-0027">28</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5 mg/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Prospective, open-label, phase I/II clinical trial</td>
<td align="left" colspan="1" rowspan="2" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Everolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">14 patients; median age : 8 years (age range, 2.0–21.3)</td>
<td align="left" colspan="1" rowspan="2" valign="top">48 months</td>
<td align="left" colspan="1" rowspan="2" valign="top">Reduction in seizure frequency in 13/14 patients (over 50% seizure reduction)</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b12-jkns-2019-0027">12</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5 mg/m<sup>2</sup>/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3" valign="top">Core phase, phase III, randomized, double-blind, placebo-controlled</td>
<td align="left" colspan="1" rowspan="3" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Everolimus</td>
<td align="left" colspan="1" rowspan="3" valign="top">366 patients (including placebo group); median age; 10.1 years (age range, 2.2–56.3)</td>
<td align="left" colspan="1" rowspan="3" valign="top">18 weeks</td>
<td align="left" colspan="1" rowspan="3" valign="top">Response rate; 15.1% with placebo 28.2% with low-exposure everolimus 40.0% with high-exposure everolimus</td>
<td align="center" colspan="1" rowspan="3" valign="top">[<xref ref-type="bibr" rid="b7-jkns-2019-0027">7</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Low exposure group; 5.2 mg/m<sup>2</sup>/day (range, 1.3–14.5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">High exposure group; 7.5 mg/m<sup>2</sup>/day (range, 1.4–24.4)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Extension phase, phase III, randomized, double-blind, placebo-controlled</td>
<td align="left" colspan="1" rowspan="2" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Everolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">294 patients; median age : 8.7 years (age range, 2.2–18.0)</td>
<td align="left" colspan="1" rowspan="2" valign="top">1 year</td>
<td align="left" colspan="1" rowspan="2" valign="top">Sustained seizure reduction in 48.05%； Median percentage reduction in seizure frequency: 48.2%</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b5-jkns-2019-0027">5</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5–9 mg/m<sup>2</sup>/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Case study series</td>
<td align="left" colspan="1" rowspan="2" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sirolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">3 patients; 15 years (age range, 5.5–21 years)</td>
<td align="left" colspan="1" rowspan="2" valign="top">Median 4 months (range, 3–5)</td>
<td align="left" colspan="1" rowspan="2" valign="top">Reduction in seizure frequency in 2/3 patients</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b6-jkns-2019-0027">6</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1.5 mg/kg/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Case report</td>
<td align="left" colspan="1" rowspan="2" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sirolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">1 patient; 9-year-old female</td>
<td align="left" colspan="1" rowspan="2" valign="top">10 months</td>
<td align="left" colspan="1" rowspan="2" valign="top">Reduction in seizure frequency</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b18-jkns-2019-0027">18</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">0.15 mg/kg/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Case study series</td>
<td align="left" colspan="1" rowspan="2" valign="top">PMSE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sirolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">6 patients; median age : 3 years (age range, 5 months–5 year)</td>
<td align="left" colspan="1" rowspan="2" valign="top">6 months</td>
<td align="left" colspan="1" rowspan="2" valign="top">Reduction in seizure frequency</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b19-jkns-2019-0027">19</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1-5 mg/m<sup>2</sup>/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Open-label, single center case</td>
<td align="left" colspan="1" rowspan="2" valign="top">TSC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sirolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">6 patients; median age : 6 years (age range, 3–17)</td>
<td align="left" colspan="1" rowspan="2" valign="top">Median duration : 18 months (range, 6–36)</td>
<td align="left" colspan="1" rowspan="2" valign="top">Over 50% reduction in seizure frequency in 5/6 patients</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b3-jkns-2019-0027">3</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1 mg/m<sup>2</sup>/day</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2" valign="top">Case report</td>
<td align="left" colspan="1" rowspan="2" valign="top">HME</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sirolimus</td>
<td align="left" colspan="1" rowspan="2" valign="top">1 patient; 3-month-old man</td>
<td align="left" colspan="1" rowspan="2" valign="top">3 months</td>
<td align="left" colspan="1" rowspan="2" valign="top">Seizure reduction (over 50%)</td>
<td align="center" colspan="1" rowspan="2" valign="top">[<xref ref-type="bibr" rid="b31-jkns-2019-0027">31</xref>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1 mg/m<sup>2</sup>/day</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>mTOR : mechanistic target of rapamycin, TSC : tuberous sclerosis, PMSE : polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome, HME : hemimegalencephaly</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>